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Biologically active peptides are a class of molecules which 
can, in ~eneral, be grouped into families of structurally related 
moieties which have a wide somatic distribution and which 
subserve multiple physiological roles. Thus, the releasing 
factors of the hypothalamus or their structural analogues may 
carry out multiple endocrine, paracrine, or neurotransmitter 
functions outside the hypothalamus. This thesis describes the 
distribution and biosynthesis of Luteinizing Hormone-Releasing 
Hormone (LH-RH) and structurally related peptides in mammalian 
tissues and tumours. 
Two strategies were employed in this investigation: 
(a) Immunological screening of tissues for suitable sources of 
LH-RH and the partial characterization of the LH-RH 
immunoreactive peptides of selected tissues; 
(b) Complemetary oligonucleotide screening of mRNA from certain 
tissues, cDNA and genomic libraries as well as genomic DNA 
restriction endonuclease fragments to establish the nature 
of the LH-RH precursor and related molecules. 
Acetic acid extracts of nineteen rat tissues were assayed in 
serial dilution for LH-RH immunoreactivity (LH-RH-IR). An 
antibody directed to the middle of the LH-RH sequence was used in 
these screening radioimmunoassays. LH-RH-IR was found in 
extrahypothalamic brain areas, in gastroenteropancreatic tissues, 
in the retina, the submandibular gland, the thyroid and the 
testes. 
In view of a putative role of endogeonous LH-RH-like 
immunoreactive peptides in intra-testicular regulation, the 
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molecular nature of the LH-RH-like material detected in rat 
testes was investigated. Acetic acid extracts of adult rat 
testes were partially purified by LH-RH-immunoaffinity 
chromatography. On Sephadex G-100 this material separated into 
four major peaks of >lOOK, -32K, -sK and <4K daltons. The <4K 
peak of LH-RH-IR eluted differently on Sephadex G-25 and 
analytical reverse phase HPLC than did synthetic hypothalamic LH-
RH decapeptide. Antibodies directed at the C-terminus of LH-RH 
gave higher estimates of LH-RH-IR for all the chromatographically 
separated testicular polypeptides than did N-terminally and 
middle directed antisera. The small testicular LH-RH-like 
peptides displaced radiolabelled LH-RH agonist from rat pituitary 
membranes more effectively than did the larger immunoreactive 
molecules. 
Monkey, pig and dog testes as well as dog Sertoli cell 
tumours were extracted with acetic acid and shown to contain LH-
RH immunoreactive material similar to that of the rat. Human 
seminal plasma was also investigated as a source of LH-RH-IR. 
When pooled seminal plasma from azoospermic males was 
fractionated by gel filtration some fractions had significant 
amounts of the rat testicular type of LH-RH. 
In order to investigate the biosynthesis of LH-RH and its 
structural variants, mRNA studies were performed, cDNA libraries 
constructed and screened together with genomic libraries and DNA 
restriction endonuclease fragments. LH-RH immunoreactive 
material was found to be associataed with membrane bound 
polysomes and not free polysomes in ovine hypothalami. This has 
been demonstrated for other secreted proteins. The Guanidinium 
Hydrochloride, Urea-Lithium Chloride, and Phenol-mCresol methods 
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of mRNA purification were used to prepare RNA for in vitro 
translation, Northern blot analysis and cDNA library 
construction. Rabbit reticulocyte lysate cell free synthesis as 
well as Xenopus oocyte translation techniques were used to 
determine the translatability of the prepared mRNA. 
Radiolabelled cell free synthesised products of hypothalamic mRNA 
translation were precipitated by antisera against somatostatin, 
but not by antisera against LH-RH. In the Xenopus oocyte 
translation system, immunoreactive LH-RH was detected in the 
incubation medium of some oocytes injected with hypothalamic 
mRNA. The small number of neurons synthesizing LH-RH relative to 
somatostatin in the hypothalamus could explain these results. 
A series of oligonucleotides complemetary to the N-terminal 
and C-terminal coding sequences of LH-RH were synthesised by the 
phosphoramidite intermediate technique. The most suitable 
oligonucleotide probes for the LH-RH mRNA sequence were deduced 
from evolutionary considerations of the known vertebrate variants 
of LH-RH. This was achieved by accommodating the changes in the 
vertebrate LH-RH sequences during evolution by presuming minimal 
base changes in the mRNA coding for the variant peptides. The 
observation that there is a significantly higher incidence of 
specific codons for any one amino acid in the neuropeptide 
hormones sequenced to date, was also used to predict the most 
likely LH-RH mRNA sequence. 
In order to investigate the nature of the LH-RH precursor, 
poly A mRNA was prepared from rat and sheep hypothalami, and two 
human mammary tumour cell lines. Rat hypothalamic mRNA species 
of -soo bases which hybridized to certain probes directed to both 
N- and C-terminal coding sequences of LH-RH. Sheep hypothalamic 
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mRNA preparations had five distinct mRNA northern blot positive 
hybridization bands of ~l.8Kb, l.45Kb, l.lKb, 0.65Kb and 0.50Kb. 
The variation in the size of mRNA species positive for LH-RH 
coding sequences in the different tissues screened could be 
unprocessed LH-RH hnRNA while the smaller species may result from 
degradation. Differential splicing during mRNA maturation could 
also explain the different sizes of LH-RH coding mRNAs. 
Alternatively, each mRNA could be an authentic mRNA arising from 
different genes coding for LH-RH itself or a LH-RH-like peptide. 
Differential splicing and 2 transcription start sites in a single 
gene have been determined to be the most likely explanation for 
these multiple RNA species. 
Primer extension studies of rat and human hypothalamic poly 
A RNA as well as human breast tumour cell line poly A RNA, 
demonstrated that the most abundant LH-RH encoding mRNA in all 
these tissues has a 5' end ~108 bases upstream from the 1st base 
of the LH-RH encoding sequence. 
Chain termination DNA sequencing of one of these clones 
established 5' end sequencing consistent with it being a full 
length clone. Examination of the human placental LH-RH cDNA 
sequence immediately upstream of the potential RNA polymerase II 
cap site indicated by this clone, revealed TATA box and CAAT box 
sequences as well as CAAT box associated Y box sequences and a 
possible enhancer core element immediately upstream from the CAAT 
box. The presence of another transcription initiation start site 
further upstream (as predicted by the human placental cDNA 
sequence) was supported by longer primer extended cDNAs in every 
tissue tested. The longer primer extended products in the 
hypothalamus indicated that the 1st intron in the gene is always 
IV 
cleaved out during mRNA maturation in this tissue while this is 
not always the case in the human breast tumour cells. 
GnRH cDNA enriched libraries of the preoptic area of rat 
hypothalamus were constructed in the plasmid pGem-3 by specific 
primer extension and restriction endonuclease digestion. LH-RH 
coding sequence positive inserts of -33ob, were obtained from 
clones from the latter two libraries. 
The Margaret Dayhoff Protein Sequence Library was scanned 
for mammalian LH-RH-like amino acid sequences. Of the protein 
and peptide sequences reported to date, one peptide has 9 amino 
acids in common with mammalian LH-RH, one has 8 in common, one 
has 7 in common, nineteen have 5 in common, while two hundred and 
seventy eight have 4 in common. These sequences include variant 
vertebrate LH-RHs, viral, bacterial, fungal and animal proteins. 
It is conceivable that a large number of these similar amino acid 
sequences have arisen independently of the LH-RH sequence. 
However, the high scores achieved by some of these sequences in 
the Mutation Data Matrix Matching of the Dayhoff protein sequence 
search for LH-RH-like sequences, suggest very strongly that a 
considerable number have arisen from an ancestral gene common to 
that of LH-RH. The fact that some of these sequences occur in 
the simplest life forms suggests that a LR-RH-structure-related 
ancestral gene arose very early in evolution. It has also been 
noted that some of the structurally related peptides have 
gonadotropin releasing activity and/or LH-RH receptor binding 
activity in in vitro bioassay systems. 
In summary, this thesis provides evidence for a LH-RH family 
of peptides in various mammalian tissues and in a wide range of 
species, similar to the other known families of neuropeptides. 
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Evidence is also provided for the existence of two 
transcriptional initiation sites in the only LH-RH gene 
characterized to date. In situ hybridization and Sl nuclease 
protection assays for LH-RH mRNA quantitation have indicated that 
LH-RH gene transcription may be upregulated in certain scenarios 
where serum LH levels are decreasing. 
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CHAPTER 1 
INTRODUCTION: NEUROPEPTIDE DISTRIBUTION AND HETEROGENEITY 
1.1 Peptide Diversity in Mammalian Brain 
In the last decade a large number of peptides originally 
characterized in non-neuronal tissues have also been found in the 
mammalian central nervous system. The converse of this statement 
is also true. Thus, for example, some of the so-called 
hypothalamic regulatory factors have been reported to occur in 
other organs and body fluids outside the brain, while some of the 
so-called gastrointestinal peptides (e.g. Vasoactive Intestinal 
Polypeptide, VIP) have been found in the brain. Three major 
concepts have -resulted from these findings, viz: 
(i) The brain contains a wide variety of peptide-containing cell 
bodies or peptidergic neurones which are distributed in 
distinct fibre pathways. In these distinct neuronal 
networks, these locally synthesised peptides are seen to 
function as neurotransmitters in their own right or as 
neuromodulators which block or alter the turnover of other 
neurotransmitters. 
(ii) Peptides either identical to or similar to the 
neuropeptides are distributed in a wide variety of tissues 
where they usually function as hormones. These non-neuronal 
peptides function in systems which are, in the greater 
part, independent of and functionally unrelated to the 
involvement of their counterparts in the central nervous 
system. 
1 
(iii)Some peptides have been co-opted for many regulatory 
functions in a wide variety of tissues during evolution. 
Table I lists the various categories of peptides which have 
now been detected in the mammalian brain. 
1.2 Families of Structurally Related Peptides 
It has been observed that among the peptides there exist 
definite groups having distinct structural similarity. Thus the 
VIP "family" of peptides includes CCK, Secretin, Gastrin, 
Glucagon, GIP (Gastric Inhibitory Peptide), PHI (Peptide having 
N-terminal histidine and C-terminal iso-leucine amide) and GH-RF 
(Growth Hormone-Releasing Hormone) (Said, 1980; Tatemoto and 
Mutt, 1980; Guillemin et al., 1982; Rivier et al., 1982). All 
the members of the VIP family have considerable amino acid 
sequence homology. 
Other peptide families include: the Opioid family of 
Endorphins, Neo-endorphins, Dynorphins and Enkephalins (Gubler et 
al., 1980; Kakideni et al., 1982); the MSH family (Liotta et 
al., 1982); the Oxytocin-Vasopressin and Neurophysin family 
(Land et al., 1982, 1983); the Insulin-Like Growth Factors (Dull 
et al., 1984); the CRF, Sauvagine, Urotensin family (Shibahara 
et al., 1983); the Gonadotropin, Thyrotropin family (Pierce et 
al., 1981); and the Growth Hormone, Prolactin, Placental 
Lactogen family (Wallis, 1975). Within each of these groups the 
peptides have striking sequence similarity. 
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Hypothalamic Releasing Factors 
Thyrotropin-Releasing Hormone (TRH) 
Gonadotropin-Releasing Hormone (Gn-RH or LH-RH) 
Corticotropin-Releasing Hormone (C-RF) 
Growth Hormone-Releasing Hormone (GH-RF) 
Somatostatin 
Pituitary Hormones 
Adrenocorticotropic Hormone (ACTH) 
Luteinizing Hormone (LH) 





Alpha Melanocyte Stimulating Hormone (alpha MSH) 
Neurohypophyseal Hormones 













Methionine - Enkephalin 
Leucine - Enkephalin 
Inverterbrate Peptides 









Calcitonin Gene Related Product (CGRP) 
Bombesin 
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1.3 Mechanisms for Generating Molecular Heterogeneity 
1 . 3.1 Differential Proteolytic Processing 
Besides the peptides having structurally similar analogues 
in different organs, the same protein precursor molecule can give 
r i se to different peptide products in different cell types. Thus 
a l though the pro-opiomelanocortin (POMC) precursor protein is 
identical in the pituitary and hypothalamus, the anterior 
pituitary produces ACTH, while the intermediate lobe processes 
all the ACTH to alpha-MSH and CLIP, and the arcuate region of the 
hypothalamus produces a mixture of ACTH, alpha-MSH and CLIP 
(Roberts et al., 1982). 
The same precursor may also be processed differentially in 
the same tissue. Thus, somatostatin-28 (SS-28), an N-terminally 
extended form of the hormone somatostatin-14 (SS-14), is a 
biologically active hormone in its own right and derived from the 
same precursor in pancreatic islet cells (Leehan et al., 1983). 
Bioactive peptides of different molecular size which are 
derived from the same precursor have also been described in the 
case of the endorphins (Rehfeld, 1978). In this instance alpha 
endorphin and gamma endorphin are respectively beta endorphin 1 
to 16 and 1 to 17. Different length bioactive forms of CCK have 
also been described (Rehfeld, 1978). The different molecular 
forms of the same peptide have been implicated in various 
physiological states and psychiatric conditions, a review of 
which was given by Krieger (1983). 
1.3.2 Other Post Translation Modifications 
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Other post-translational modifications that can give rise to 
molecular heterogeneity include amidation, acetylation, 
sulphation, phosphorylation, glycosylation and assembly of sub-
units. As an example of the latter case, the gonadotropins share 
a common alpha subunit but have different beta subunits. 
1.3.3 Differential hnRNA Splicing 
Peptide heterogeneity may potentially also arise through 
differential splicing of nuclear RNA during mRNA maturation. 
Thus different mRNAs could be obtained from the same transcribed 
gene by the inclusion or exclusion of certain exons of the gene. 
When these mRNAs are translated they would give rise to different 
protein products which may have tracts of sequence homology. The 
calcitonin gene with four coding exons in the primary transcript 
appears to undergo differential splicing in different tissues. 
Thus, the CGRP (calcitonin gene related peptide) encoding 
sequence occurs in the calcitonin mRNA of some tissues but not 
others (Amara et al., 1982). 
1.3.4 Gene Duplication 
Gene duplication and subsequent mutation within daughter 
genes is the main mechanism by which families of structurally-
related peptides arise. The Brockman body in the pancreas of the 
anglerfish has two closely related mRNAs both giving rise to SS-
14 (Hobart et al., 1980). This is probably a case of recent gene 
duplication since there is considerable sequence homology between 
the two genes. The glycoprotein hormones LH, FSH, TSH and hCG 
share a common alpha subunit but have different beta subunits 
5 
which have arisen due to multiple gene duplications over a more 
extensive period of evolution. (Pierce et al., 1981). 
1.4 The LH-RH Family of Peptides 
There has been no evidence for a LH-RH family of peptides 
until very recently. Indeed, only ten years ago, the idea of 
non-ribosomal synthesis of LH-RH was still favoured by some 
investigators (McKelvy and Snyder, 1978). This method of peptide 
synthesis does not, however, appear to be involved in the 
generation of peptide diversity in mammals. In support of 
ribosomal synthesis, however, there was a considerable body of 
evidence that higher molecular weight forms of LH-RH do occur 
(Kerdelhue, et al., 1973; Barnea and Porter, 1975; Fawcett, et 
al., 1975; Millar et al., 1977, 1978, 1980; Gautron et al., 
1981). None the less, no irrefutable evidence had been provided 
of the exact size of the precursor(s) that give(s) rise to the 
hypothalamic decapeptide LH-RH. Cell free synthesis followed by 
immunoprecipitation of the products with an LH-RH antiserum had 
suggested that the primary LH-RH precursor in rat, mouse and 
human hypothalami is a 28,000 molecular weight protein (Curtis 
and Fink, 1983a, 1983b). Recently the cDNA sequence of a 
placental LH-RH precursor has revealed that it is a 92 amino acid 
protein (-10,000 molecular weight) (Seeburg et al., 1984). It 
has since been reported that the LH-RH mRNA may undergo 
differential splicing in the human hypothalamus and the placenta 
(Adelman et al., 1986). This does not however effect the LH-RH 
protein precursor since the difference in splicing occurs in the 
5' untranslated region of the mRNA. 
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Besides the identification of a wide variety of higher 
molecular weight LH-RH immunoreactive proteins, four peptides 
with sequences dissimilar from the mammalian decapeptide have 
been detected in vertebrates. Thus Gln 8-LHRH has been identified 
in chicken hypothalami (King and Millar, 1982), while His
5 , 
Trp7, Tyr8-LH-RH has been identified as another form in chicken 
brain (Miyamoto et al., 1984); Trp7 , Leu8-LH-RH was isolated 
from salmon brain (Sherwood et al., 1983), and in the lamprey 
Tyr3, Leus, Glu6, Trp7 , Lys 8-LH-RH has been described (Sherwood 
et al., 1985). Using antisera specific for Gln 8 LH-RH, Millar 
has detected Gln8-LH-RH in mammalian extra-hypothalamic brain 
(Millar et al., 1987). Ovine pineals have been shown to contain 
a peptide similar to Gln 8 LH-RH as distinguished by 
chromatographic systems (Millar et al., 1986). Mammalian gonadal 
LH-RH has been shown to be structurally distinct from the 
hypothalamic decapeptide (Dutlow and Millar, 1981). Other non-
neuronal sources of LH-RH immunoreactivity include the placenta 
(Khodr et al., 1980), pancreas (Seppala and Wahlstrom, 1979) and 
milk (Amarant et al., 1982). LH-RH receptors have been 
demonstrated in a wide variety of tissues and tumours suggesting 
that extrahypothalamic sources of the peptide or its related 
molecules have physiological roles outside the pituitary. The 
low circulating levels of the hypothalamic LH-RH argue against 
the hypothalamus being the source of the peptide involved at the 
non- pituitary target tissues. Tissues having LH-RH receptors 
include the pituitary (Clayton et al., 1979), the placenta 
(Currie et al., 1981), the testes (Sharpe and Fraser, 1980; 
Millar et al., 1982), the ovary (Popkin et al., 1983), the 
adrenals (Bernardo et al., 1978; Eidne et al., 1985), the 
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prostate (Hierowski et al., 1983) and breast tumours (Eidne et 
al., 1985). The different affinities of the receptors of 
different tissues for LH-RH agonists and antagonists could be 
seen as suggestive of different endogenous ligands, i.e. peptides 
similar to but distinct from the mammalian hypothalamic LH-RH 
decapeptide. 
A number of lines of evidence are thus indicative of a wide 
distribution of LH-RH and structurally related peptides in 
mammalian tissues and tumours. There is also a wide distribution 
of so-called LH-RH receptors which display different ligand 
binding characteristics and there exists therefore, structural 
diversity of receptors. A working hypothesis that can be 
developed from these observations is that there may be receptor 
specificity for the variant forms of LH-RH-like peptides produced 
at different sites. The privacy of communication which is well 
documented in the hypothalamic hypophyseal portal system could 
thus be expanded to include other scenarios for specific 
regulatory roles of the different, but related peptides at other 
tissue sites. The gonadal peptide could thus be thought to 
function in paracrine regulation of reproductive function. There 
is also a developing body of evidence supportive of an autocrine 
growth regulatory role for a number of peptides (Stiles, 1984; 
Cuttitta et al., 1985). The success of LH-RH antagonists in 
treating certain tumours having LH-RH receptors could be an 
indication of a growth regulatory role of endogenous LH-RH 
variants in certain tissues (Tolis et al., 1982; Harvey et al., 
1984; Eidne et al., 1985). 
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CHAPTER 2 
DISTRIBUTION OF LH-RH IMMUNOREACTIVE PEPTIDES 
2.1 INTRODUCTION 
Based mainly on his earlier studies of the pituitary portal 
circulation (Green and Harris, 1949), Harris proposed in 1955 
that parvocellular neurons of the hypothalamus receive inputs 
from other neurons in the central nervous system via synaptic 
contacts and secrete factors into the portal vessels to regulate 
hormone release from the anterior pituitary (Harris, 1955). This 
basic premise has subsequently been confirmed by the isolation 
and elucidation of the structure of the following hypothalamic 
factors: thyrotropin-releasing factor (Boler et al., 1969); 
gonadotropin-releasing factor (Matsuo et al., 1971); 
somatostatin (growth hormone release inhibiting factor) (Burgus 
et al., 1973); corticotropin-releasing factor (Vale et al., 
1981); growth hormone-releasing factor (Rivier et al., 1982; 
Esch et al., 1983). The chemical synthesis of these hypothalamic 
peptides and the development of radioimmunoassays for them, 
greatly extended the information about their control of anterior 
pituitary function. However, since the releasing factors are 
present in minute quantities (in the order femtomoles/mg of the 
hypothalamus) (Guillemin et al., 1981), biosynthesis studies have 
proven particularly difficult. The investigation of other 
possible sources of larger amounts of the peptide releasing 
factors became a necessary avenue of study in attempting to 
delineate their biosynthetic pathways. Indeed, this approach has 
recently rewarded investigators with the determination of the 
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complete structure of the somatostatin precursor in the angler 
fish endocrine pancreas (Hobart et al., 1980), the frog skin TRH 
precursor (Richter et al., 1984), and a human pancreatic islet 
tumour GH-RF precursor (Mayo et al., 1983). It has, in fact been 
known for a considerable oeriod of time that a wide variety of 
tumours are a source of ectopic hormones (Bloom et al., 1979). 
Also, in 1966 Pearse postulated a common embryological origin for 
cells of the so-called diffuse neuroendocrine system (Pearse, 
1966). He later suggested that the common origin was the 
neuroectoderm and proposed that the endocrine system was an 
"outpouch" of the brain (Pearse, 1969). Working on this premise 
numerous investigations have now shown that the nervous and 
endocrine systems synthesize a large number of identical or 
related peptides. 
It was with the above facts in mind that the distribution of 
LH-RH-IR in extrahypothalamic brain, non-neuronal tissues and 
tumours was investigated. 
2.2 SURVEY OF RAT TISSUE FOR LH-RH-IR 
Nineteen rat organs and brain regions were dissected from 50 
adult male Wistar rats. Acetic acid extracts of these tissues 
were assayed in serial dilution for LH-RH-IR. The LH-RH 
antiserum (antiserum 1076) used in the radioimmunoassays of 
tissue extracts has been shown to be highly specific for the 
middle portion of the mammalian LH-RH decapeptide (see Fig. 3.'l--j 
(Millar et al., 1984). However, since cross-reacting related 
peptides could conceivably be detected by this radioimmunoassay, 
the immuno-reactive peptides detected in certain tissues were 
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subjected to further characterization by radioimmunoassay with 
other antibodies and by high performance liquid chromatography. 
2.2.1 Methods 
2.2.1.1 Acetic Acid Extraction 
The dissected tissues were collected on solid co2 and stored 
at -20°c. The tissues were homogenized in two volumes of 2N 
acetic acid at 4°c using an Ultra-Turrax homogenizer. When a 
uniform homogenate was obtained, extraction was further 
facilitated by incubation at 4°c for 2h. The homogenates were 
centrifuged at 18,000g for 30 minutes at 4°c and the clear 
supernatants were lyophilized. The lyophilized extracts were 
reconstituted in 0.02N acetic acid, recentrifuged at 18,000g for 
30 minutes and the clear supernatant serially diluted in 0.02N 
acetic acid and subjected to radioimmunoa~say. 
2.2.1.2 Radioimmunoassay 
LH-RH was iodinated by the chloramine T protocol (Hendricks 
et al., 1975) and purified by chromatography on Dowex 1X8 and CM-
32 cellulose ion exchange resins (Millar et al., 1984). In a 
typical assay each assay tube contained 10,000 cpm of the peptide 
radiolabelled to a specific activity of approximately 1000 
uCi/ug. The antiserum was used at a final dilution in the assay 
of 1:100,000. The assay was performed in a final volume of 
500 ul of phosphate buffered saline (PBS) (pH 7.0) containing 
0.1% gelatin and the protease inhibitor bacitracin at a final 
concentration of 10-4M. All samples and standards were added to 
the assay tubes in 0.02N acetic acid. The assay tubes were 
incubated at 4°c for 18h. 750 ul of 0.5% charcoal (Norit A) 
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coated with 0.05% dextran T70 in PBS was added to the assay tubes 
and incubated at 4°c for 15 minutes to separate antibody-bound-
from free-125I-LH-RH. The tubes were centrifuged at 1000g for 15 
minutes at 4°c and supernatants containing the antibody-bound 
peptides were counted in a multi-well gamma counter. The 
displacement from antibody of radiolabelled peptide by 
immunoreactive material in the standards and samples was 
expressed relative to the amount of radiolabelled peptide bound 
by antibody in the absence of unlabelled LH-RH standard (%B0 ). 
The LH-RH-IR in each tissue extract was expressed relative to the 
total peptide extracted as determined by the Lowry protein assay 
(Lowry et al., 1951). 
2.2.2 Results and Discussion 
The acid extracts of a number of tissues were found to 
contain "LH-RH binding proteins." These were evidenced in the 
radioimmunoassay by the higher levels of the radiolabelled 
peptide in the antibody bound fraction, relative to the amount 
bound when only radiolabelled peptide and antibody are present. 
In order to correct for these factors in the assay their ~v(,..t-(~fti 
~ f 
contribution to the binding of radiolabelled peptide was measured ~{ 
in the absence of antibody (called the non-specifically bound- .J 
fraction). This was done for each dilution of the tissue extract 
in question. The amount of non-specifically bound radiolabelled 
peptide (evaluated in cpm) was subtracted from the amount bound 
in the presence of antibody, thus giving the number of counts 
specifically bound by antibody. 
Protease contamination of samples in a radioimmunoassay is 
usually evidenced by less radiolabelled peptide in the antibody 
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bound fraction of the assay due to degradation of either the 
antibody or the radiolabelled peptide, or both. This would be 
reflected in the assay as an apparently high level of 
immunoreactive peptide in the sample. The presence of 
immunoreactivity in tissue known to contain high levels of 
proteases, e.g. the pancreatic LH-RH-IR, should therefore be 
interpreted with caution. 
Table 2.1 and figure 2.1 show that LH-RH-IR was detectable 
in a number of tissue extracts. The specific activity of these 
immunoreactive peptides is in every case much less than in the 
hypothalamus. Besides being an accurate reflection of the LH-RH 
content of certain tissues, the results in certain cases could be 
due to the underestimation of an LR-RH-related peptide which has 
low cross-reactivity in this assay. The more detailed 
characterization of the LH-RH-IR in testes described in chapter 3 
of this thesis supports the latter explanation. The pineal gland 
of sheep has recently been shown to contain a peptide similar to 
Gln8-LH-RH (Millar et al., 1987). This peptide is known to show 
low cross-reactivity in the radioimmunoassay using antiserum 
1076. 
The presence of LH-RH-IR in other areas of the brain has 
also been documented by other workers (Silverman et al., 1976 and 
Ibata et al., 1983). The possibility that the LH-RH found in 
extra-hypothalamic brain performs a neurotransmitter or 
neuromodulator role deserves investigation. 
LH-RH was found in a number of tissues involved in 
reproductive functions. Immunocytochemical evidence for a local, 
"private", i.e. paracrine, pituitary LH-RH system has been 
presented (Yuan Li et al., 1984). Being a target organ for 
13 
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Fig. 2.1 DISPLACEMENT OF 12~1 LH-RH FROM ANTISERUM 1076 BY
 
SERIAL DILUTIONS OF ACETIC ACID EXTRACTS OF RAT TISSUES 
The synthetic peptide used was quantified by weight and 
the protein concentration of the extracts by the method 
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Table 2.1 LH-RH-IR IN 19 RAT TISSUES 
Concentrations were determined 
curves shown in figure 2.1. 
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hypothalamic LH-RH, it is also possible that the pituitary 
immunoreactive peptides described in this and other studies are 
measurable because of concentration at this site due to the 
peptide binding to the pituitary receptors, internalization, etc. 
The testicular LH-RH-IR described here, was further 
characterized (chapter 3). Another source of LH-RH is the 
placenta (Khodr et al., 1980). It has been proposed that the LH-
RH synthesized in placental cytotrophoblasts regulates the 
placental production of hCG in syncytiotrophoblasts (Hsueh et 
al., 1981). Human and bovine milk has also been shown to contain 
LH- RH-IR (Amarant et al., 1982). Because other hormones 
including TRH, prolactin, the opioid casomorphin and ACTH have 
been found in milk, it has been proposed that they have 
physiological roles in the suckling mammalian neonate (Hazum, 
1983). 
LH-RH-IR was found in a number of gut regions and gut 
associated organs. The fact that LH-RH-IR is found in different 
parts of the gut is an extension of the group of so-called brain 
and gut peptides (Powell et al., 1979). LH-RH-IR in the pancreas 
has also been reported by others (Seppala et al., 1980). It is, 
furthermore, reported that LH-RH inhibits insulin release from 
isolated rat pancreatic islets (Klier et al., 1980) suggesting 
that the immunoreactive material in the pancreas may have a 
regulatory role in glucose metabolism. Additional support for a 
role of LH-RH in glucose metabolism is the fact that glucose 
oxidation and incorporation into fatty acids in rabbit adipose 
tissue is increased by LH-RH (Murthy et al., 1974). 
The presence of LH-RH-IR in the submandibular gland is also 
of interest since it has been demonstrated that the submandibular 
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glands of cats contain hypolemmal axons containing large dense 
core granular vesicles of the peptidergic type (Kidd et al., 
1979). Another neuropeptide found in submandibular glands is 
vasoactive intestinal polypeptide (Wharton et al., 1979). 
LH-RH-IR was also found in a number of other tissues. The 
presence of LH-RH in the retina is reminiscent of reports on the 
presence of other neuropeptides in the retina (Eskay et al., 
1980). It is tempting to speculate that the LH-RH in retina has 
a role in vision since certain patients suffering from the LH-RH 
deficiency disorder, Kallmann's syndrome, present with colour 
blindness (Kallmann et al., 1944). LH-RH may also be implicated 
z 
in the sensory pathways of smell since some Kallmann's patients 
f,(( 141 
suffer from anosmia and LH-RH has been reported in the olfactory 
system (Philips et al., 1980). 
The fact that LH-RH-IR is detectable in the skin could be an 
indication of innervation of the skin by LH-RH neurons. The role 
of the peptide at the periphery could be related to its effect on 
glucose metabolism, should it be located in the subcutaneous 
adipose tissue. It is also feasible that peptide location in 
mammalian skin is a vestige of the large amounts of the so-called 
neuropeptides (e.g. TRH) found in amphibian skin (Jackson et al., 
1977). 
The rat thyroid contains significant amounts of LH-RH. The 
thyroid gland has recently also been found to contain the 
neuropeptides substance P, CCK, ACTH, beta endorphin, and beta 
lipotropin (Ahren et al., 1983; Clements et al., 1982). 
Since the kidney may be a site of catabolism and clearance 
of LH-RH, as for proteins and peptides in general, the presence 
17 
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of LH-RH-IR in kidney extracts could arise from a concentrating 
effect in this organ of LH-RH and/or its degradation products. 
This study thus confirms the location of LH-RH-IR at a 
number of extrahypothalamic sites. However, due to the 
relatively small amounts of the peptide(s) in these tissues 
investigation of the mechanism of biosynthesis of LH-RH was seen 
to be more feasible in the hypothalamus. Further confirmation of 
the actual sites of synthesis of the peptide found in these 
extrahypothalamic tissues is required. The physiological role of 
the peptide(s) at these sites is certain to engender 
investigation in the future. 
2.3 SURVEY OF TUMOURS AND CELL LINES FOR LH-RH-IR 
2.3.1 Introduction 
Since ectopic production of many hormones occurs in a number 
of tumours, acetic acid extracts of human tumours and tumour cell 
lines were assayed for LH-RH-IR. The cell lines included a 
number of mouse and human neuroblastoma cell lines, human 
melanoma cell lines as well as other lines of epithelial origin. 
Solid tumours included dog Sertoli cell carcinomas, human 
pancreatic tumours (including one which was shown to be producing 
large amounts of somatostatin) and a human buccal tumour cell 
line grown in nude mice. 
Of all the cell lines and tumours tested only the human 
buccal tumour cell line was shown to be producing significant 
quantities of LH-RH-IR. The buccal tumour line HEp-3 was first 
described in 1954 and believed to be neuro-ectodermal in origin 
(Toolan, 1954). It has been successfully passaged in tissue 
culture and in nude mice (Miskin et al., 1981). This cell line 
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has recently been shown to synthesize high levels of VIP (Gozes 
et al., 1983). The nature of the LH-RH- IR in this cell line 
was analysed by radioimmunoassay with several antisera directed 
to different parts of the mammalian LH-RH, as well as by HPLC. 
One of the antisera (F86) used in this study had not been 
previously characterized. Thus, in order to define the region of 
the mammalian decapeptide to which this antiserum was directed, 
the cross reactivity of a series of LH-RH analogues and fragments 
in a radioimmunoassay with this antiserum were tested. 
2.3.2 Methods 
2.3.2.1 Characterization of Antiserum F86 
This antiserum was kindly supplied by Dr. S. Lynch. The 
cross-reactivities of LH-RH analogues in the LH-RH 
radioimmunoassay using this antiserum were calculated from the 
concentrations (by weight) of the analogues which decreased the 
binding of 125 1-LH-RH to the antiserum by 50% (i.e. the ED50 ). 
The percent cross reactivity for a particular analogue or 
fragment was thus estimated by dividing the Eo50 of that peptide 
by the ED50 of standard LH-RH and multiplying by 100. From the 
degree of cross-reactivity of a number of analogues in the assay, 
deductions were made as to the specificity of the antiserum i.e. 
which amino acids in LH-RH are essential for binding by this 
antiserum. 
2.3.2.2 Peptide Extraction 
The protocol was essentially as outlined in 2.2.2.1 except 
that two extraction solutions were used, viz: 
a) 2N acetic acid in methanol; 
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b) 2N acetic acid containing 10-4M bacitracin. 
These protocols were used in order to assist in the first 
instance with delipidation of some tumour samples, and in the 
second instance to inhibit proteases known to be synthesised by 
the tumour. 
2.3.2.3 Radioimmunoassays 
Six different LH-RH antisera were used to quantitate the LH-
RH-IR in tumour extracts. Antibodies 1076 and 743 are directed 
at the middle of the LH-RH sequence (Millar et al., 1984). 
Antiserum 80/1 requires both the N- and C-termini for binding 
(King et al., 1983), while antiserum CRR11B73 is nominally C-
terminally directed. Antiserum F86 was shown in this study to 
require the N-terminus of LH-RH for binding, while being 
sensitive to the conformation of the molecule as well. Antiserum 
YKl has not been fully characterized. 
2.3.2.4 HPLC 
Three different reverse phase HPLC systems were used: 
a) In the first system a micro Bondapak Cl8 column was used. 
Samples of tumour extract were injected in 1 ml 0.1% TFA. 
Solution A was 1% acetonitrile in 0.1% TFA and solution B, 
80% acetonitrile in 0.1% TFA. A linear gradient was run 
from 0% to 100% B over 60 minutes at 1 ml per minute and 1 
ml fractions were collected. 
b) In the second system a Vydac Cl8 column was used. Samples 
were injected in 1 ml of 0.1% heptafluoro butyric acid 
(HFBA). Solution A was 0% acetonitrile, 0.1% HFBA and 
solution B, 60% acetonitrile, 0.1% HFBA. The sample was 
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injected onto the column which had been pre-equilibrated in 
30% Band run at this% B for 10 minutes. The gradient was 
altered to 50% B over 20 minutes, kept at this% B for 10 
minutes, altered to 100% B over 5 minutes and kept at 100% B 
for 5 minutes. The flow rate was 1.5 ml per minute and 1.5 
ml fractions were collected. 
c ) In the third system a Spherisorb Cl8 column was used. 
Samples were injected in 1 ml of O.OlM ammonium acetate (pH 
4.0). Buffer A was 0% acetonitrile in O.OlM ammonium 
acetate, while buffer B was 60% acetonitrile in 0.004M 
ammonium acetate. The column was equilibrated to 40% B 
before the sample was injected. After injection the buffer 
was maintained at 40% B for 20 minutes. It was then altered 
to 60% B over 5 minutes, kept at 60% B for 25 minutes, taken 
to 99% B over 5 minutes and kept at 99% B for 5 minutes. 
The flow rate was 1.5 ml per minute and 1.5 ml fractions 
were collected. 
In each system, duplicate 100 ul aliquots of each fraction 
were lyophilized and assayed for LH-RH immunoreactivity. 
2.3.3 Results and Discussion 
Antiserum F86 was shown by the cross-reactivity studies to 
be directed to the N-terminus of LH-RH. Thus, it does not 
tolerate changes in this part of the molecule and therefore 
cross-reacts very poorly with LH-RH analogues altered or lacking 
in amino acids at the N-terminus. The antiserum displays 
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The cross reactivities were calculated from the 
concentrations (by weight) of the analogues which 
decreased the binding of 12~1 LH-RH to the antiserum by 
50%. The data indicates that the antiserum requires 
the N-terminus of LH-RH for binding. The antiserum is 
conformation-sensitive as well, since alterations in 
the middle of the LH-RH molecule decrease the% cross-
reactivity. Glr is important for binding, since the 
beta-II type bend induced at this position brings the 









T~~le 2~ RADIOIMMUNOASSAY OF HEp-3 TUMOUR EXTRACTS WITH SIX 
LH-RH ANTISERA. 
The discrepancies in quantitation by the different 
antisera is most probably due to the presence in the 
extracts of the two forms of LH-RH-IR shown in figure 
2.2. 
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poorly with analogues that have amino acid substitutions in the 
middle of the molecule. LH-RH is believed to contain a beta-II 
type bend in the middle of the molecule. Substitutions in this 
region of the molecule either stabilize or relax this 
conformation (Friedinger et al., 1980; Spatola, 1983). 
Radioimmunoassay of the crude extract of the HEp3 tumour by 
the six antisera gave a range of LH-RH-IR estimates in the tumour 
from 1.8 ng/g tissue with antiserum 1076 to 4.7 ng/g tissue with 
antiserum YKl (Table 2.3). When the extracted material was 
applied to the first reverse phase system (Fig. 2.2a) a major 
peak of immunoreactivity eluted earlier that mammalian LH-RH. 
Another extract of the tumour when run on the second reverse 
phase system resolved into two immunoreactive peaks detected by 
antiserum 1076, one coincident with the elution position of the 
mammalian decapeptide and the other an earlier eluting peak (Fig. 
2.2b). 
A LH-RH-IR profile similar to that of the second HPLC system 
was obtained in the third system (Fig. 2.2c). 
The immunoreactive material eluting earlier than the 
mammalian hypothalamic decapeptide was re-assayed with antisera 
F86, CRR11B73 and 80/1. The N-terminally directed antiserum gave 
an estimate of the immunoreactivity similar to that of antiserum 
1076, while both the nominally C-terminally directed antiserum 
CRR11B73 and the N- and C-terminus . requiring antiserum 80/1 did 
not detect the first peak. One interpretation of these data is 
that the earlier eluting peptide is another variant form of the 
LH-RH decapeptide and is modified at the C-terminus. 
Alternatively, it could be a C-te:trninally extended form, i.e. a 
precursor and/or an incompletely processed form of the mammalian 
23 
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Fi_g__._--2...,_2 REVERSE PHASE HPLC OF HEp-3 TUMOUR EXTRACTS 
Three reverse phase HPLC systems known to separate 
Chicken I-, Chicken II-, Mammalian- and Salmon-LR-RH 
(see text) were used to determine the nature of the LH-
RH-IR extracted from the HEp-3 buccal cell tumour. In 
all three systems a predominant early peak (less 
hydrophobic than mammalian LH-RH) was seen. This peak 
did not coincide with that of any of the vertebrate LH-
RH' s. Whether this peak is a fragment or precursor 
form of the mammalian peptide or a novel peptide has 
not been determined. 
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decapeptide (e.g. lacking an amidated C terminus). The fact that 
the mammalian decapeptide is not present in some extracts, as 
evidenced in the first HPLC system, could be due to processing or 
degrading proteolytic enzymes being present at variable 
concentrations from one preparation of the tumour to the next 
(e.g. a reflection of the stage of the tumour when harvested from 
the nude mice). 
Since the HEp3 tumour produced large amounts of poly A mRNA 
(5-10% of total RNA - see chapter 5) the nature of the LH-RH 
precursor was further investigated by northern blot analysis and 
cDNA cloning as outlined in Chapter 5. 
2.4 CONCLUSIONS 
This survey of extra-hypothalamic tissues and tumours has 
demonstrated a wide distribution of LH-RH-IR. This pattern was 
previously described for a number of peptides initially detected 
either in the brain or the gastro-intestinal tract. Based on the 
effects of LH-RH at different sites, e.g. in the pancreas or in 
the gonad, it is highly likely that LR-RH-like peptides 
synthesized outside the hypothalamus and identical to or related 
to LH-RH, may serve functions different from the gonadotropin-
releasing activity observed at the pituitary. The potential for 
a peptide to function as a neurotransmitter or releasing factor 
or paracrine hormone depending on its site of synthesis becomes a 
valid concept considering the above data and deserves future 




GONADAL LH-RH-LIKE PEPTIDES 
3.1 INTRODUCTION 
Porcine hypothalamic LH-RH was originally isolated by virtue 
of its ability to stimulate release of the anterior pituitary 
hormones luteinizing hormone (LH) and follicle stimulating 
hormone (FSH) (Matsuo et al., 1971). The positive regulatory 
role that hypothalamic LH-RH has via the pituitary gonadotropins 
on gonadal steroidogenesis, ovulation in the female and 
spermatogenesis in the male has been demonstrated in a number of 
vertebrates (Schally, 1978). However, repeated or prolonged 
administration of high doses of LH-RH or its agonists to a number 
of species results in inhibitory, "paradoxical" effects on 
reproductive function. Thus, in females, chronic administration 
of LH-RH agonists results in a decrease in ovarian 
steroidogenesis (Yoshinaga, 1979), a decrease in ovarian 
gonadotropin receptors (Kledzik et al., 1978), inhibition of 
follicular maturation and ovulation (Berquist et al., 1979), 
delay of puberty (Johnson et al., 1976), delay of implantation 
and pregnancy termination (Corbin et al., 1975), delay of 
parturition (Bereu et al., 1980), and decrease in uterine and 
oviductal growth (Rippel et al., 1976). In males, chronic LH-RH 
agonist treatment decreases testicular androgen production (Haug 
et al., 1974), decreases testicular gonadotropin receptor content 
(Auclair et al., 1977), decreases testicular weight (Sandow et 
a l ., 1978), inhibits spermatogenesis (Pelletier et al., 1978), 
and decreases the growth of the ventral prostate and seminal 
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vesicles (Oshima, et al., 1975). It was initially proposed that 
the high doses of LH-RH used in these situations cause 
desensitization of the pituitary to respond to the normal 
positive stimulation by the decapeptide on LH and FSH release. 
However, it has been demonstrated that high doses of LH-RH can 
decrease testicular function without concomitant decreases in 
serum gonadotropin levels (Rivier et al., 1979). These anti-
fertility effects are partly due to "down regulation" of gonadal 
gonadotropic hormone receptors resulting from LH-RH induced 
elevation of pituitary FSH and LH levels (Auclair et al., 1977), 
but direct effects of LH-RH on the gonads have also been 
described (Sharpe et al., 1983). High affinity receptors for LH-
RH have been demonstrated on the cell membranes of ovarian 
granulosa (Clayton et al., 1979) and luteal cells (Marwood et 
al., 1980) and on testicular interstitial cells (Millar et al., 
1982; Sharpe et al., 1981). The occurence of these LH-RH 
receptors in the gonads and the demonstration that gonadal 
function is altered by LH-RH administration in hypophysectomized 
animals argues for a direct involvement of LH-RH-like peptides in 
the control of ovarian and testicular function in vivo. Since 
hypothalamic LH-RH is released into the portal veins at low 
concentrations (Eskay et al., 1977); is rapidly degraded by the 
pituitary (Griffiths et al., 1981) and is found in 
infinitesimally small amounts in the peripheral circulation 
(Eskay et al., 1977), there may be a local source of LH-RH or a 
related peptide within the gonad which is involved in the 
regulation of reproductive function via a local receptor mediated 
mechanism. Since a local source of LH-RH or a related peptide in 
the gonads has been proposed by the rationale outlined above and 
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s i nce LH-RH immunoreactivity (LH-RH-IR) was found in rat testes 
as described in the distribution studies of the previous chapter, 
chromatographic and immunological cross reactivity approaches 
were used to further characterize the rat testicular LH-RH-IR. 
3.2 RAT TESTICULAR LH-RH-IR 
3.2.1 Methods 
3 . 2.1.1 Acetic Acid Extraction 
390 rat testes were collected on solid co 2 and stored at 
-20°c. The testes were homogenised in two volumes of 2N acetic 
acid at 4°c by three 5-10 sec. bursts with an Ultra-Turrax 
homogenizer. Homogenates were centrifuged at 18,000g for 30 
minutes at 4°c and the clear supernatants were lyophilized. The 
peptide concentrations in the extracts and subsequent column 
fractions, etc. were determined according to the method of Lowry 
(Lowry et al., 1951). 
3.2.1.2 Immunoaffinity Chromatography 
The lyophilized extract was reconstituted in O.SM ammonium 
acetate (pH 7.0) and centrifuged at 18,000g for 30 minutes at 
4°c. The clear supernatant was subjected to batch-wise affinity 
chromatography using anti-LH-RH antiserum 1076 (Millar et al., 
1984) conjugated to Sepharose 4B (Axen et al., 1967). The 
testicular extract was mixed with the resin in roller bottles for 
3 hours at room temperature. Unbound non-immunoreactive material 
was removed by several washes with O.SM ammonium acetate (pH 
7.0). LH-RH-IR bound to the affinity gel was eluted with five 
washes of 80 ml of 1.SM acetic acid (until pH 2.8 was reached) 
and lyophilized. To neutralize the affinity resin, the acid was 
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replaced by O.SM ammonium acetate and washing continued until the 
pH of the eluant reached pH 7.0. 
3.2.1.3 Sephadex G-100 Chromatography 
The material partially purified by immunoaffinity 
chromatography was reconstituted in a small volume of 2N acetic 
acid containing 8M guanidinium chloride, incubated at so 0 c for 3 
hours and subjected to Sephadex G-100 chromatography. The 
protein content of the eluant was monitored by ultraviolet 
absorption at 280 nm. Immunoreactive LH-RH was detected by 
radioimmunoassay using antiserum +076. 
3.2.1.5 Sephadex G-25 Chromatography 
The lower molecular weight immunoreactive peptides (-sooo 
daltons and less) eluted off the G-100 column were chromato-
graphed on Sephadex G-25. 
3.2.1.5 Reverse Phase HPLC 
Lyophilized acetic acid extracts of rat testes were 
reconstituted in 1% TFA and slowly passed through three Waters 
Sep-pak C-18 cartridges in tandem. The cartridges were washed 
thoroughly with 1% TFA and the bound material eluted with 60% 
acetonitrile, 1% TFA. The eluted peptides were lyophilized and 
subjected to reverse phase HPLC on a Vydac C-18 column as 
outlined in 2.3.2.4(b). Under the conditions used in this 
protocol four synthetic vertebrate-LH-RH-decapeptides were shown 
to be separated from each other. 
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3.2.1.6 Antibody Binding Studies 
The different molecular forms of the LH-RH-IR separated by 
Sephadex G-100 and Sephadex G-25 chromatography were subjected to 
radioimmunoassay by antisera directed against different regions 
of the mammalian hypothalamic LH-RH decapeptide (Millar et al., 
1984). The relative quantitation of LH-RH-IR peaks by these 
antisera yielded information on possible differences in structure 
between the testicular peptides and the hypothalamic LH-RH. 
3.2.1.7 Pituitary Receptor Binding 
The various species of LH-RH-IR separated on Sephadex G-100 
were used to displace 1251 labelled LH-RH agonist from pituitary 
membranes according to the method of Millar (Millar et al., 
1982). 
3.2.2 Results and Discussion 
The crude acetic acid extract of 390 rat testes contained 
54.5 ng of LH-RH-IR with a specific activity of 2.93 ng/g peptide 
using antiserum 1076. After affinity chromatography of 17.4 ng 
of LH-RH-IR, the specific activity increased SO-fold to 165 ng/g 
peptide. Sephadex G-100 chromatography of a portion of the 
affinity purified material revealed four major LH-RH-like 
peptides (I, II, IV and VI) with apparent molecular weights of 
>100,000, N32,000r NS,000 and ~4,000 (Fig. 3.1). When the low 
molecular weight peptides from the G-100 column were subjected to 
chromatography on Sephadex G-25, the major peak of immuno-
reactivity emerged later than the mammalian hypothalamic 
decapeptide (Fig. 3.2). The testicular peptides having LH-RH 
immunoreactivity were shown by reverse phase HPLC to include a 
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s pecies that elutes in a position similar to that of chicken II 
LH-RH, i.e. Hiss, Trp7 , TyrB-LH-RH (Fig. 3.3). Three other 
elution peaks, not coincident with any of the vertebrate LH-RH 
peptides were also observed on HPLC. 
When all six peaks of LH-RH-IR of the G-100 column were 
quantitated with antisera specific for different regions of the 
mammalian hypothalamic decapeptide (Fig. 3.4), antiserum 744 
which is directed against the -COOH terminus of the mammalian 
peptide (Millar et al., 1977) consistently gave higher_ 
estimations of LH-RH-IR than did antisera 1076 and R42 which 
recognize the middle of mammalian LH-RH and both termini 
respectively (Millar et al., 1977; Nett et al., 1973). 
When pituitary membranes were used to assay for LH-RH 
receptor-binding ligands in the Sephadex G-100 peaks of 
testicular LH-RH-IR, it was observed that there was increased 
receptor-binding activity as the size of the material tested 
decreased (Fig. 3.5). The quantitation by this assay of 
testicular LH-RH receptor-binding-peptide in peak VI off the G-
100 column was approximately 80 times more than the LH-RH-IR 
determined in this peak by antiserum 744. 
The presence of a number of ~olecular size forms of LH-RH-IR 
in rat testis is an indication that a peptide similar to the 
hypothalamic decapeptide may be synthesized by processing from a 
precursor protein in the testis. The higher molecular weight LH-
RH-IR species demonstrated by molecular sieve chromatography 
could be precursors of a peptide which when fully processed may 
be similar in size to the hypothalamic decapeptide. It must be 
noted, however, that even though strong denaturing conditions (BM 
guanidinium hydrochloride, 2N acetic acid) were used for the 
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Sephadex G-100 chromatography, the possibility of aggregation of 
the lower molecular weight peptides and/or their binding to other 
proteins under these conditions, cannot be entirely excluded. 
The observation that the testicular LH-RH-like peptides elute 
later on Sephadex G-25 than does the hypothalamic peptide is not 
necessarily an indication that the peptide is smaller since 
adsorptive behavior has been observed for a number of peptides 
chromatographed on molecular sieve columns (Gautron et al., 
1981). Although the testicular peptide that is more hydrophobic 
than the mammalian hypothalamic decapeptide elutes in a position 
similar to that of chicken II LH-RH on HPLC, more detailed 
studies are required to determine whether it is in fact chicken 
II LH-RH. 
The antibody binding studies could be viewed to be 
supportive of the testicular peptide being different from the 
chicken II LH-RH. Antiserum 744, which binds to amino acids 
Arg8, Pro9, GlyNH 2 of the mammalian hypothalamic peptide, 
recognizes the testicular peptide better than do the other 
antisera tested. The implication of the antibody-binding studies 
is that the testicular peptide shows C-terminal homology with the 
mammalian decapeptide. It is, however, in this region that the 
chicken II LH-RH (His 5 , Trp7 , Leu8-LH-RH) differs from the 
mammalian hypothalamic peptide. A similar study on rat testis 
extracts has described testicular LH-RH immunoreactive material 
which may share C-terminal sequences with mammalian hypothalamic 
LH-RH (Bhasin et al., 1983). In contrast, another study 
described rat testicular peptides which reacted more poorly with 
C-terminally-directed LH-RH antisera than antisera which 
recognize either both termini or the middle region of the 
32 
molecule (Turkelson et al., 1983). The conflicting reports 
regarding the implied structural differences between the 
testicular and hypothalamic LH-RH-immunoreactive peptides may be 
due, in part, to the presence of multiple precursor forms of the 
peptide in crude extracts. Proteolytic degradation and/or 
aggregate formation and/or co-purification of peptide binding 
proteins could also explain the discrepancies. Two groups have 
recently demonstrated gonadal LH-RH-like peptide which are more 
hydrophobic on reverse phase HPLC than the mammalian decapeptide 
(Aten et al., 1985; Iwasaki et al., 1985). The observation that 
pituitary membrane LH-RH receptors bind the testicular peptide 
better than any of the antibodies used in this study could be 
exploited in the further purification and characterization of 
this peptide. 
Since large numbers of rat testes would have to be extracted 
in order to purify gonadal LH-RH-IR in sufficient quantities for 
structural analysis, other sources of the peptide were 
investigated. 
3.3 LH-RH-IR IN TESTES OF OTHER MAMMALS 
In order to investigate whether other mammalian species have 
testicular LH-RH-IR, acetic acid extracts were made of rabbit, 
monkey and pig testes. Since there are some indications that 
Sertoli cells are the site of synthesis of the LH-RH variant 
peptide (Sharpe et al., 1981) pig testis tubules were prepared as 
a potential source of enriched levels of the peptide. Since 
Sertoli cell carcinomas are known to be common in certain breeds 
of dog (Lipowitz et al., 1973) extracts of such tumours were also 
tested for LH-RH-IR. 
33 
160 1. 6 
140 1. 4 
120 1. 2 




60 0 . 6 
40 0 . 4 






40 60 80 100 120 140 




Fig . 3.l SEPHADEX G-100 CHROMATOGRAPHY OF AFFINITY PURIFIED RAT 
TESTICULAR LH-RH-IR. 
3.5ng of LH-RH- IR, partially purified by affinity 
chromatography was reconstituted in 2N AcOH, BM 
GuHCl,incubated at 50°C for 3h, placed on a Sephadex 
G-100 column (86.5cm x 5cm) and eluted with 2N AcOH at 
a flow rate of 30ml/h at 4°C. 30min fractions were 
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F1..9:_._3.2 SEPHADEX G-25 CHROMATOGRAPHY OF LH-RH AND POOLED 
TESTICULAR LH-RH-IR PEAKS V AND VI OFF SEPHADEX G-100 
Fig 3. 1>. 
The G-25 co 1 umn ( 87. 5cm x 1. 7cm) was run at 4°C at a 
flow rate of 12ml/h and 30min fractions were collected. 
Material placed on the column was in 2N AcOH, 8M GuHCl 
and eluted with 2N AcOH. Lyophilized column fractions 
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Fi~~ VYDAC C18 REVERSE PHASE HPLC OF RAT TESIS ACETIC ACID 
EXTRACTS. 
20 rat testes were extracted in 2N AcOR. The 
lyophi 1 ized extract was passed through 3 Sep-pak C-18 
cartridges in 1% TFA and the retained peptides eluted 
in 60% acetoni tri le, 1% TFA. The 1 yophi 1 ized e 1 uant 
was applien to the column in 1 ml of the starting 
buffer and chromatographed as outlined in 2.3.2.4(b). 
Prior to this col.umn run, fractions from a blank run, 
performed under identical conditions, were assayed and 
shown not to contain LR-RH-IR. The four vertebrate 
forms of LR-RH were shown to elute in the positions 
indicated in subsequent column runs under identical 
conditions. 
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Fig. 3.4 ESTIMATION BY THREE ANTISERA OF LH-RH-IR IN THE POOLED 
SEPHADEX G-100 PEAK FRACTIONS OF RAT TESTIS EXTRACT 
(Fig.3.1>. 
The parts of the LH-RH molecule to which the three 
antisera are directed are indicated. This information 
was obtained from cross reactivity studies using LH-RH 
analogues and fragments in the radio immunoassay 
employing these antisera (see Table 2. 2). Antiserum 
744 CC-terminally directed) estimated the amount of 
LH-RH-IR in each of the pooled peaks to a greater 
extent than did antisera 1076 (middle directed) and 
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Fig. 3. 5 DISPLACEMENT OF 12::sr LABELLED LH-RH AGONIST FROM RAT 
PITUITARY MEMBRANES BY TESTICULAR LH-RH-IR SIZE 
FRACTIONATED ON SEPHADEX G-100 
Five of the six peaks of LH-RH-IR separated on Sephadex 
G-100 (Fig. 3.1) were serially diluted and assayed for 
LH-RH receptor binding activity using rat pituitary 
membranes. The smaller LH-RH-IR species consistently 




3.3.1.1 Seminiferous Tubule Preparation 
A decapsulated pig testis weighing 470 g was rinsed in a 
buffered solution of 2.SmM (pH 7.2), 137mM NaCl SmM KCl, 0.7mM 
Na 2HP0 4 . The testis was then incubate
d at 35°c for 15 minutes in 
r i nse solution containing 0.4 mg% collagenase (140 IU/mg), 10 
ug/ml DNase and 1% BSA. The tubules were then centrifuged at 
1000 g for 10 minutes at 4°c and washed thrice with 0.9% saline 
at 4°c. 
3.3.2. Results 
Assay of testis and seminiferous tubules of different 
mammalian species with the three LR-RH-site-specific antisera 
shown in figure 3.6 gave similar relative quantitation as for the 
rat (see Fig. 3.4). No significant enrichment of the peptide was 
achieved either by removing the interstitial cells from pig 
testes (Fig. 3.6) or by extracting histologically confirmed 
Sertoli cell carcinomas of dogs (Fig. 3.7). 
3.4 LH-RH-IR IN HUMAN SEMINAL PLASMA 
Since high doses of exogenously administered LH-RH agonists 
have antifertility effects at the level of the testis it could be 
envisaged that certain classes of infertility in man may be due 
to pathologically high levels of the testicular LH-RH variant. 
Thus, a number of semen specimens were obtained from a fertility 
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Fig. 3.6 LH-RH-IR IN THE TESTES OF THREE VERTEBRATE SPECIES 
Acetic acid extracts of monkey, pig, and rabbit testes 
were examined as potential sources of testicular LH-RH-
IR for purification. The material in all cases was 
estimated to the same degree by Ab 744 and Ab 1076 as 
for the rat testis extract, indicating that the same 
peptide is present in these species. No enrichment was 
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Fig. 3. 7 RADIO IMMUNOASSAY OF DOG TESTIS AND DOG SERTOLI CELL 
CARCINOMA EXTRACTS FOR LH-RH-IR 
Acetic acid extracts of normal dog testes (samples 1, 2 
and 5) and Sertoli cell carcinomas (samples 3 and 4) 
were assayed for LH-RH-IR using Ab 1076. Non-parallel 
displacement indicating the presence of a peptide 
disimi lar from the mammalian decapeptide was obtained 
in all cases. The Sertoli cell carcinomas did not 
prove to be an enriched source for the peptide. 
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3.4.1 Methods 
Because of the high levels of proteases in seminal plasma 
(Lundquist et al., 1955) the following peptide extraction 
protocol was followed. Semen samples were placed directly in 
liquid nitrogen when collected. The snap frozen samples were 
placed directly into a boiling water bath and incubated at 100°c 
for 30 minutes. The samples were placed on ice and made 0.2N 
with respect to acetic acid which had been pre-cooled to 4°c. 
The protease inhibitors Bacitracin and p-Chloro Mercuric Benzoate 
were added to concentrations of 10-4M and 10-5M respectively 
(Horsthemke et al., 1980). The samples were incubated at 4°c for 
30 minutes and centrifuged for 30 minutes at 18,000 g. The 
supernatants were lyophilized and reconstituted in 0.02N acetic 
acid containing the two inhibitors listed above and assayed for 
LH-RH-IR. 
3.4.2 Results 
Enhanced binding of radiolabelled LH-RH was observed when 
assaying all human semen extracts for LH-RH-IR. The binding of 
radiolabelled LH-RH by semen extracts in the absence of antibody 
made detection of LH-RH-IR extremely difficult. However, the 
presence of low levels of LH-RH-IR could be extrapolated by 
) subtracting the binding factor component of the assay from the 
antibody plus binding factor components (i.e. the enhanced or 
total binding figure) (Fig. 3.8). 
Sephadex G-25 fractionated semen samples were obtained from 
the laboratory of Dr. Peter Gray of the University of the Orange 
Free State (Gray et al., 1984). In the case of normozoospermic 
and oligospermic seminal plasma chromatographed on Sephadex G-25, 
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no LH-RH-IR was detectable in any of the column fractions. 
However, the chromatographed azoospermic seminal plasma had two 
fractions with a significant level of LH-RH-IR. The inability to 
detect any LH-RH-IR at all in the column fractions of the 
chromatographed normozoospermic and of oligozoospermic semen 
samples, obtained from Dr. P. Gray, could be due to the fact that 
stringent steps were not taken to eliminate proteolytic 
degradation of peptides prior to the column runs. As for the LH-
RH-IR extracted from a number of species, the azoospermic seminal 
plasma column fractions were recognized to a greater extent by 
the C-terminally directed antiserum (antiserum 774) than by the 
antisera requiring either both termini or the middle region of 
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Fi_g_, _  3 . 8 RADIOIMMUNOASSAY OF SERIALLY DILUTED HUMAN SEMEN 
SAMPLES FOR LH-RH-IR 
Assay of human semen extracts for LH-RH-IR initially 
showed the presence of LH-RH binding factors in a 11 
cases (evidenced by enhanced binding of 125 !-LH-RH in 
the assay) . When no antibody was added to the assay 
tubes, the binding component due to these factors was 
noted. Subtraction of this "non-specific-binding" 
component in the assay enabled the estimation of low 
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Fig~,._2_ RADIOIMMUNOASSAY OF POOLED FRACTIONS OF SEPHADEX G-25 . 
CHROMATOGRAPHED SEMEN EXTRACTS 
Pooled semen samples from either normo-, oligo-, or 
azoospermic individuals were extracted for peptides and 
size fractionated on Sephadex G-25 columns. Pooled 
fractions were assayed for LH-RH-IR using antisera 1076 
and 744 . LH-RH-IR was only observed in fractions of 
the azoospermic semen sample. Estimation by Ab 744 was 
higher than by Ab 1076 indicating that the same peptide 
found in rat, pig, dog and rabbit testes is present in 
h uman semen. Whether the relatively high levels of the 
peptide have a pathological role in azoospermia 
deserves further investigation. 
I ( 7 
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3 . 5 CONCLUSIONS 
There exist in mammalian gonads, peptides which are 
recognized by some antisera raised to hypothalamic LH-RH. The 
peptides can bind to the LH-RH receptors of pituitary 
gonadotrophs and may serve as the endogenous ligand for the 
previously described Leydig cell "LH-RH receptors". The peptide 
probably results from the processing by proteolytic cleavage of 
larger precursor forms. The physiological role of the gonadal 
peptide is not yet known. The effect of exogenous LH-RH on the 
enzymes of the steroidogenic pathway is, however, strongly 
suggestive of a paracrine role for the testicular peptides in 
regulating steroidogenesis (Jones et al., 1981, 1982; Hsueh et 
al., 1980). High levels of the endogenously synthesized peptide 
may also play a role in the pathophysiology of azoospermia, as 
suggested by this study. The relatively high levels detected in 
the seminal plasma from patients with this disorder and the fact 
that such a condition can be induced in laboratory animals by 
high levels of LH-RH agonists is supportive of such a Y,oO 
V 
pathological role for the peptide (Labrie et al., 1980). 
Evidence has recently been provided for a LH-RH-like glycoprotein 
of between 10,000 and 30,000 daltons in pooled human semen (Sokol 
et al., 1985). The peptide does not seem to be involved in the 




DESIGN AND SYNTHESIS OF LH-RH OLIGONUCLEOTIDES 
Synthetic oligonucleotides have proven effective in 
detecting complementary polynucleotides. DNA detection by 
o l igomers employed in Southern Blot hybridization (Montgomery et 
al., 1978); cDNA synthesis using oligonucleotides as primers 
(Smith, 1980); and RNA detection by Northern Blot analysis with 
small synthetic probes (Thomas, 1980) have become established 
techniques in characterizing the mammalian genome, specific mRNAs 
and, by inference, specific polypeptides. The rapid chemical 
synthesis of oligonucleotides by the phosphoramidite intermediate 
technique (Caruthers, 1982) and the advances made in recombinant 
DNA technology have made it possible to investigate the nature of 
peptide hormone precursors (Eiden, 1982). The extremely low 
concentrations of LH-RH in hypothalamic tissue (N300 ng/g wet 
. tissue) (Palkovits et al., 1974) has made the application of cDNA 
oligonucleotides and recombinant DNA technology a more feasible 
alternative than classical protein isolation and sequencing to 
establish the nature of the LH-RH precursor. As in the cases of 
somatostatin (Hobart et al., 1980) and the opioid family of 
peptides (Gubler et al., 1982), recombinant DNA techniques could 
potentially verify the existence of genes related to the LH-RH 
gene. Oligonucleotide primer extension studies could also be 
employed to characterize the 5' end of LH-RH encoding mRNAs. 
Transcription start sitee and potential promoter and enhancer 
sequences could then be deduced from gene sequencing studies. 
Solution phase hybridization and 5' nuclease protection assays 
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using oligonucleotides could also be used to quantitate low 
levels of LH-RH mRNA. 
4.1 DESIGN OF cDNA PROBES 
There is a high degree of codon degeneracy for certain of 
the amino acids in the LH-RH decapeptide. There are in fact 
110,592 unique 30-mer mRNA sequences that could code for the 
peptide (Table 4.1). In order to simplify the task of 
determining the most likely probes for mammalian LH-RH mRNA the 
following strategies were employed. 
4.1.1 Origin of the C-and-N-Terminal Amino Acids 
LH-RH is "blocked" at both termini by unusual amino acids, 
viz. pyroglutamic acid at the N-terminus and glycine-amide at the 
C-terminus. The pyroglutamic acid (pGlu) of peptides is derived 
from glutamine (Gln) in precursor polypept_ides. In all the cases 
investigated to date Gln is the amino acid which becomes cyclised 
during the processing of the precursor polypeptide (Millar, et 
al., 1978, 1981; Folkers, et al., 1981; Abraham et al., 1981). 
Glutamic acid (Glu) can also be chemically converted to pGlu but 
there is no evidence that this is the origin of pGlu in 
ribosomally biosynthesised polypeptides. 
Structural analysis of a number of C-terminally amidated 
peptides has revealed that they are all derived from precursors 
having a glycine (Gly) residue C-terminally adjacent to the 
amidated amino acid (Millar et al., 1978, 1981). Furthermore, a 
pituitary amidating enzyme has been demonstrated to have an 
absolute requirement for Gly on the C-terminal side of the amino 
48 
acid which undergoes oxidative transamidation (Bradbury et al., 
1982). 
On the basis of these studies, Gln was assumed to be the 
precursor of pGlu1 , and Gly11 the donor of the amino group to the 
C-terminal Gly1 0NH 2 of LH-RH. 
4 . 1.2 Heptadecamer Probes for N-Terminal Coding Sequences 
Statistically, an oligonucleotide of ''n" nucleotides occurs 
only once at random in a polynucleotide target when 4n is the 
number of nucleotides in the polynucleotide (Thomas, 1966; 
Smith, 1984). For the mammalian genome as the polynucleotide 
(~10 10 bases), n=l7. 
In order to synthesize fewer oligonucleotide probes for the 
LH-RH mRNA sequence, the mRNA sequence was divided into a N-
terminal coding region and a C-terminal coding region. 
Heptadecamer probes for both mRNA stretches could then be used in 
parallel experiments to identify mRNA species having sequence 
homology to both probes. From the statistical argument presented 
above, a mRNA species which hybridizes to both groups of 
oligonucleotides has a high likelihood of being LH-RH encoding. 
The N-terminal section of LH-RH from pGlu1 to Gly6, was chosen 
for the synthesis of the first group of cDNA oligonucleotide 
probes. The third nucleotide of the Gly6 codon was eliminated 
resulting in a heptadecamer sequence having only 48 
possibilities. It was decided to synthesize all the likely cDNA 
heptadecamer probes for the LH-RH N-terminal coding sequence in 
three groups of 16 oligonucleotides viz. groups Ll, L2, L3 (Table 
4 • 2 ) 
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Codons G ln 1 Hi s Trp Ser Tyr Gly Leu Arg Pro G ly 1 c::• 
5 ' CAA CAU UGG UCN UAU GGN CUN CGN CCN GGN 3 ' 
G C AGU C UUA AGA 
C G A 
Cod Q.D.$_.E_~r: 
.9,.mi11.o acid, 2 2 1 6 2 4 6 6 4 4 
No of unigu~ 
30-mer~ 110 592 
Table 4.1 CODON DEGENERACY FOR LH-RH AMINO ACIDS 
The high degree of redundancy in the coding for the 
amino acids that constitute the LH-RH decapeptide 
indicates that the authentic 30-mer sequence coding for 
LH-RH is one of 110 592 possibilities. 
LH-RH N-Terminus Gln1 His Trp Ser Tyr Gly6 
Codon~ 5' CAA CAU UGG UCN UAU GGN 3 ' 
G C AGU C 
C 
01 i...9:.omer Mixt_1,1re L 1 3' GTT GTA ACC AGA ATA cc 5' 
C G G G 
L 2 3' GTT GTA ACC AGC ATA cc 5' 
C G T G 
L 3 3' GTT GTA ACC TCA ATA cc 5 ' 
C G G G 
Table 4.2 cDNA OLIGONUCLEOTIDES FOR LH-RH GLN 1 - GLV0 
The 48 possible unique heptadecamers comp 1 imentary to 
the RNA encoding the N-terminus of LH-RH were 
synthesized as three groups of 16 oligonucleotides 
each, viz . 11, 12 and 13. 
so 
4.1.3 Probes for C-Terminal Coding Sequence 
The diversity in mRNA sequence for the C-terminal section of 
LH-RH from Gly6 to Gly11 was more extensive. The heptadecamer 
sequence which excluded the last nucleotide of the Gly11 triplet 
included 1,536 possibilities. 
4 . 1.3.1 Natural Codon Frequency Considerations 
In order to determine the most likely LH-RH C-terminus 
encoding sequences, the codon incidence for each amino acid 
represented at the C-terminus was examined in a number of 
neuropeptide hormone and brain protein messengers. It has been 
I 
observed that there exists in eukaryotic mRNA a natural frequency 
of codon selection for each of the amino acids (Estratiades et 
a l ., 1977; Shine et al., 1977). In order to see whether such a 
preference for certain codons exists in the mRNAs of neuropeptide 
hormones and brain proteins, seven such mRNAs were examined. 
Table 4.3 indicates that such a frequency of codon selection does 
exist in these polypeptide messengers. This information was then 
used to choose the most likely codons to screen for in the mRNA 
for the LH-RH C-terminus (Table 4.5). 
4.1.3.2 Arg~ Codons: Evolutionary Considerations 
In the case of codons for Arg, the third nucleotide is 
represented to a similar extent by both C and G bases. Since 
mammalian LH-RH may have evolved from an ancestral molecule which 
also gave rise to avian Gln8-LH-RH (King et al., 1982) the codon 
representing single point mutations from Gln to Arg were 
examined. Two possibilities exist as demonstrated in Table 4.4. 
Since CGG (as opposed to CGA) is the codon occuring most 
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LH-RH C-Terminus 
amino acids Gly6 Leu Arg Pro9 
Codon _Incidence 
i n 7 .E.O l_y_pe.E.t ides GGC5a C1::s::sUG ... 4 C54GG2a 
G26 C::s2 C::so 
U 1::S A14 A14 
Ae U17' U14 A27 u ... 
Table 4_.3 CODON FREQUENCY FOR THE LH-RH C-TERMINUS AMINO ACIDS 
The incidence of the various codons for each amino acid 
of t~e LH-RH C-terminus was determined in mRNAs 
encoding 7 polypeptides viz. the ACTH-precursor 
(Nakanishi et al, 1979), the Vasopressin precursor 
(Land et al,1982), the Calcitonin precursor (Jacobs et 
al, 1981), the Enkephalin precursor (Noda et al, 1982), 
the Tubulin precursor (Ginzburg et al, 1981), the Human 
Growth Hormone precursor (Martia l et al, 1979) and the 
Somatostatin precursor (Hobart et al, 1980). The codon 
incidence in al 1 the mRNAs for each individual amino 
acid followed the same general trend for all 7 
polypeptides. 
Amino Acid Che!_~ Gln8 -> Arg8 
Codon Changes 1 Mutation : CAG -> C§G 
CAA -> C§A 




Table~ Gln8 -> Arg 8 MUTATION POSSIBLE CODON CHANGES IF 
MAMMALIAN LH-RH AROSE FROM CHICKEN-I LH-RH 
A single point mutation of the second nucleotide of the 
Gln° triplet of chicken-I LH-RH could give rise to the 
mammalian peptide . If this assumption is correct, it 
would indicate that the Arg8 codon is either CGG or 
CGA. Since the CGG codon occurs at a higher frequency 
in mammalian mRNA, it was chosen as the most likely 
codon for Arg9 in the mammalian peptide. 
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frequently in the mRNAs listed in Table 4.3, it was chosen as the 
most likely triplet to represent Arg 8 in the mammalian LH-RH 
message. 
4.1.3.3 LH-RH C-Terminus: Most likely cDNA Probes 
On the basis of the case presented above four oligonucleo-
tides for the C-terminal coding region of LH-RH, were 
synthesized. These are shown in Table 4.5 as oligonucleotide 
group L4. It has been demonstrated that dG-rU mismatches do not 
effect duplex stability during hybridization (Lomart et al., 
1975). Thus in the case of Gly6 and Gly10 , three codon 
possibilities, viz. GGC, GGG and GGU could hybridize to the 4 
probes synthesised. The cDNA triplet for Leu (GGG) would also 
hybridize to the CCU codon. The initial group of four probes 
(L4) would thus effectively hybridize to 18 unique sequences. In 
the event of other mismatches, the high G-C content of these four 
probes (16 out of 17 bases) would counteract the duplex 
instability to some degree (Lipsett et al., 1964; Smith, 1984). 
4.1.3.4 Probes for statistically less probable LH-RH C-terminus 
coding sequences 
Since the above reasoning is only useful in deriving the 
most likely codons and can not guarantee the actual sequences, 
other cDNA oligonucleotides representing the LH-RH C-terminus 
were also synthesised viz. L5-L8 (Table 4.5). In order to reduce 
the number of C-terminal oligomers synthesized while increasing 
the number of sequences screened, 14-mers were chosen. The 64 
oligomers synthesized on this basis would screen for two-thirds 
of all the possible LH-RH C-terminal coding sequences. Since 
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LH-RH C-Terminus Gl¥6 Leu Arg Pro G 1 y10Ntk 
LH-RH Precursor Gly6 Leu Arg Pro Gly Gly11 
"Preferred" Codons 5' GGC CUG CGG CCC GGC GG 3' 
G G 
Oligonucleotide Mixture L4 3' CCG GAC GCC GGG CCG cc 5 ' 
Table 4.5 
C C 
L5 3' CCA GAA GCC GGG cc 5' 
G G T T 
L6 3' CCA GAC GCC GGG cc 5' 
G T T T 
L7 3' CCC GAA GCC GGG cc 5' 
T G T T 
L8 3' CCC GAC GCC GGG cc 5' 
T T T T 
OLIGONUCLEOTIDE PROBES FOR LH-RH C-TERMINAL CODING 
SEQUENCES 
L4 was synthesized as a mixture of heptadecamers. The 
decision to have both G and C as the third base in the 
case of the Gly codons in L4 was taken since 82% of the 
G 1 y residues of 7 po 1 ypept ides were encoded by these 
two codons (Table 4. 3) . CGG was the codon of choice 
in the case of Arg-8 for the reasons indicated in Table 
4. 4. L5, L6, L7 and LS are each mixtures of 16 
oligonucleotides. Thus, 64 of the 144 possible unique 
sequences for this section of the LH-RH encoding 
message would be screened by these four mixtures . 
Having G as the third base in the probe for the Pro9 
codon would facilitate dG:rU matching as well, enabling 
each of the 16 probes to hybridize to 24 unique 
sequences. Thus, 96 of the possible 144 coding 
sequences fer this part of the LH-RH would hybridize to 
these probes. 
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t hese C-terminal probes would only serve as secondary 
confirmatory probes for LH-RH mRNAs detected unequivocally by the 
N-terminal probes, their size was not seen to be in conflict with 
the statistical limits deduced by Thomas and Smith (Thomas et 
al., 1966; Smith et al., 1984). Small probes of this length and 
even shorter have been demonstrated to be very effective in 
identifying unique polynucleotide sequences (Wallace et al., 
1981; Furutani et al., 1983; Richter et al., 1984). 
4.2 SYNTHESIS OF LH-RH OLIGONUCLEOTIDES 
The use of solid support polymeric carriers has greatly 
simplified the multistep synthesis of oligonucleotides of defined 
sequence. The macromolecular support serves to protect one of 
the nucleotide chain termini and provides an efficient and easy 
method of separating the attached growing biopolymer from soluble 
reactants. The method of Caruthers employing silica as the solid 
support system and deoxynucleoside phosphoramidites as the 
building blocks was slightly modified and used to synthesize the 
LH-RH cDNA oligomers (Caruthers, 1982; Beaucage et al., 1981). 
4.2.1 Synthesis of the Support 
Synthesis of the oligonucleotide takes place in the 3' to 5' 
d irection. The initial step thus involves attachment of the 
activated first nucleotide at the 3' end of the oligomer to an 
activated silica gel support. 
4.2.1.1 Activation of Silica Gel 
HPLC grade silica gel was exposed to a saturated LiCl 
solution for 24 hours. The silica was then treated with 3-
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triethoxysilylpropylamine in dry toluene for 12 hours at 20°c. 
After low speed certrifugation, the gel was washed three times 
with each of the following solvents: toluene; methanol; and 
50% methanol in water. The silica was shaken in 3-triethoxy-
silylpropylamine in toluene at 20°c for 18 hours. It was then 
washed in methanol and ether and dried in vacuo. The dry silica 
was then suspended in anhydrous pyridine, treated with 
trimethylsilyl chloride for 12 hours at 20°c, washed with 
methanol and ether and dried in vacuo. 
4.2.1.2 Attachment of Nucleoside to Activated Silica. 
The dry silica was suspended in dimethyl formamide (DMF) and 
a solution of the 5'-dimethoxytrityl nucleoside-3'-p-nitrophenyl 
succinate in dioxane and triethylamine was added. The suspension 
was shaken at 20°c for 4 hours. Free amino groups on the silica 
were measured with ninhydrin. To acylate or "cap'' these groups, 
acetic acid was added to the resin and shaken for 30 minutes, 
after which a negative ninhydrin test resulted. The silica was 
then washed with DMF followed by ether and dried in vacuo. In 
order to analyse the extent of nucleoside attachment to the solid 
support, an accurately weighed sample of silica (10-15 mg) was 
treated with 5 ml of 72% perchloric acid: ethanol (3:2 v/v) and 
the optical density of the supernatant after centrifugation was 
measured at 497 run (an acid solution of dimethoxytritanol has an 
extinction coefficient of 70,000 cm mole-1 ). A typical 
preparation yielded 60-80 moles of bound nucleoside per g of 
silica. 
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4.2.2 Synthesis Procedure 
The derivatized nucleosides were added in molar excess to an 
appropriate quantity of resin by the following general scheme. 
4 . 2.2.1 Deblocking the Attached Nucleoside 
The appropriately derivatized deoxynucleoside attached 
covalently to the silica was treated with 2% trichloroacetic 
acid (TCA) in dichloromethane for 0.5 min and then washed with 
f resh TCA solution. 
Three thorough washes each with dichloromethane, 
acetonitrile and dry acetonitrile, under a nitrogen atmosphere, 
prepared the activated nucleoside for condensation. 
4 . 2.2.2 Condensation 
Stock solutions of protected 2'-deoxynucleoside-3-N,N 
dimethylaminomethoxyphosphines in dry acetonitrile and sublimed 
tetrazole in dry acetonitrile were stored under nitrogen. These 
were_ added to the silica-attached deoxynucleoside in excess (10 
molar excess for the phosphine and 50 molar excess for the 
tetrazole). Condensation occured under the inert gas atmosphere 
for 5 minutes. The silica was then washed with tetrahydrofuran 
(THF). 
4.2.2.3 Capping 
Unreacted hydroxyl groups were acylated for 2 minutes with 
0.6N dimethyamino pyridine in dry THF mixed with 6N acetic 
anhydride in 2,6 Lutidine (4:1 v/v). The blocked nucleoside 
attached to the resin was then washed with THF. 
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4.2.2.4 Oxidation 
The trivalent phosphorus was oxidised to pentavalent 
phosphate with O.lM iodine in THF: 2,6 Lutidine: H20 (2:1:1 
v / v) for 3 minutes. 
The solid support-bound dinucleotide was then washed with 
THF, methanol and dichloromethane. This reaction cycle was 
repeated for each nucleotide that was attached. 
4.2.3 Release of Oligonucleotide from Solid Support 
The methyl blocking groups were removed from the oligomers 
prior to their release from the support by ammoniolysis. 
Demethylation of the oligonucleotide on the solid support was 
achieved by incubating the silica with thiophenol: triethylamine: 
dioxane (1:1:2 v/v) for 75 minutes. After washing with methanol 
and dichloromethane, the silica was suspended in 25% aqueous 
ammonia and kept sealed at room temperature for 18 hours. Fresh 
ammonia was added and the reaction continued at ss 0 c for 12 
hours. The liquid phase was then evaporated to dryness. 
4.2.4 Purification of the Oligonucleotides 
The dry oligonucleotide was resuspended in sterile water and 
an aliquot was loaded onto a 20% Acrylamide BM Urea preparative 
gel and electrophoresed in TBE at 20 mA constant current for 3 
hours. The oligonucleotides were visualized over a fluorescent 
silica plate under UV irradiation. The relevant oligomer bands, 
as determined from standards of different oligonucleotide length 
were cut from the gel with a scalpel blade. The gel slice was 
crushed and extracted overnight in O.SM ammonium acetate, lOmM 
magnesium acetate, lmM EDTA and 0.1% SOS (Maxam et al., 1977). 
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Th e oligonucleotide was then desalted on a Sephadex G-25 column 
(1 cm x 10 cm) and eluted with sterile water. The pooled void 
vo lume peak of UV absorbing (OD 26 onm) oligonucleotide was 
lyophilized and stored dry or as aliquots in TE at -20°c. 
4.2.5 Confirmation of Oligonucleotide Sequence 
The chemically synthesised oligomers were radioactively 
labelled at the 5' terminus with 32P by the T4 polynucleotide 
k i nase catalysed reaction (Maxam et al., 1977). The sequences 
were confirmed by Dr. M. Bodner employing a modified Maxam-
Gi lbert chemical degradation sequencing technique. 
4.3 OTHER PROBES 
4.3.1 A Deoxyinosine Containing Oligonucleotide 
DeoxyiDosine insertion in oligonucleotide probes at 
ambiguous codon positions has recently been described as an 
alternative to synthesizing probes with mixtures of nucleotides 
i n the wobble position (Ohtsuka et al., 1985). A 17-mer probe 
having inosine in positions of coding degeneracy for the N-
terminus codons of LH-RH was synthesized for this study by Bill 
Huse of Yale University. This probe (L9) should hybridize to the 
N-terminal coding sequences for all the vertebrate LH-RHs except 
the recently described lamprey sequence (Table 4.6). 
4 . 3.2 Unique Probe Deduced from the Human LH-RH Precursor cDNA 
During the course of this study, the sequence of the human 
placental LH-RH precursor was established (Seeburg et al., 1984). 
A unique 18-mer probe for the precursor mRNA was synthesized for 
this study by Dr. Srivastava of Chemgenes Inc., Boston. This 
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1 Mammalian LH-RH 
2 . Chicken-I LH-RH 
Gln 1 His Trp Ser Tyr Gly Leu Arg Pro Gly10 
Gln° 
Trp7 Leu0 
1 _ C.l1i cken-I I LH_-:.Rtl 
Possible Codons 
His5 Trp7 T'/,e 
f o.r._L2._c;...nd_Q 5'CAA 
G 
CAU UGG UCN UAU GGN 3' 
C AGU C 
C 
Possible CodQDS 
for3 5 ' ••••••••••••••••• CAT. . . • 3 ' 
Probe L9 3'GTI GTI ACC AGI ITI CC 5' 
Table 4.6 L9 - A PROBE WITH INOSINE AT AMBIGUOUS CODON POSITIONS 
Probe L9 was designed to hybridise to the mRNAs of all 
the known vertebrate LH-RHs except that of the recently 
described lamprey peptide. The N-terminal amino acids 
of these LH-RH variants is conserved to a greater 
degree than in the lamprey peptide 
(Tyr3,Leu5 ,Glu6 ,Trp7 ,Lys0 -LH-RH). Having inosine in 
positions of coding redundancy permits hybridisation of 
L9 to any of the 64 possible sequences encoding these 
LH-RHs (Ohtsuka et al, 1985). 
ij.Pl. LH-RH Precursor 11-16 
H.Pl .LH-RH mRNA 
Oligonucleotide LlO 
Gly11 Lys Arg Asp Ala Glu16 
5' GGA 
3' CCT 
AAG AGA GAT GCC GAA 3' 
TTC TCT CTA CGG CTT 5' 
Tab 1 e 4 . 7 OL I GONUCLEOT I DE PROBE L 10 A UN I QUE PROBE FOR THE 
HUMAN PLACENTAL LH-RH mRNA 
The mRNA sequence encoding the first 6 amino acids 
immediately C-terminal to LH-RH in the precursor was 
chosen to derive a unique cDNA probe for the human 
LH-RH mRNA and gene. 
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oligonucleotide (LlO) is directed to a region of the precursor 
mRNA immediately 3' of the LH-RH coding sequence (Table 4.7). 
4.3.3 A 34-mer Common to the Human, Rat and Mouse LH-RH 
Precursor cDNAs 
The LH-RH precursor encoding mRNA in the human placenta 
(Seeburg et al., 1984), human hypothalamus (Adelman et al., 1986) 
rat hypothalamus (Adelman et al., 1986) and as deduced from the 
mouse gene (Mason et al., 1986a) were compared for sequence 
homology. The longest stretch of sequence homology in these 
mRNAs was found to be a 34 base sequence encoding amino acids -6 
to +6 of the precursor protein (Table 4.8). A 34-mer 
oligonucleotide complementary to this region of the LH-RH mRNA 
was synthesized for this study by the Oswel DNA service of 
Edinburgh (Table 4.8). 
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aa -6 -1 +1 -6 
H Val Glu Gly Cys Ser Ser Gln His Trp Ser Tyr Gly 
5 · GTG GAA GCC TGC TCC AGC CAG CAC TGG TCC TAT GGA 3· 
R/M Leu . .... . ......... · ........................ . .... 
5· T .............. . ..... . ......... . . . ............ G 3· 
Lll 3 · AC CTI CCG ACG AGG TCG GTC GTG ACC AGG ATA cc 5· 
Tq.b l e 4. 8 OLIGONUCLEOTIDE PROBE L11 - A UNIQUE PROBE FOR ALL 
LH-RH GENES SEQUENCED TO DATE. 
Oligonucleotide Lll is directed at the longest stretch 
of sequence homology shared by the human (H), rat (R) 
and mouse (M) LH-RH genes viz. the part encoding the 
first 6 amino acids of LH-RH and the adjacent 6 amino 
acids of the leader peptide. The dots indicate 




LH-RH PRECURSOR MRNA, DNA AND GENE REGULATION STUDIES 
5.1 INTRODUCTION 
In order to extend the study of the nature of the LH-RH 
precursor and related peptides, the oligonucleotide probes 
synthesized as outlined in the previous chapter were used to 
analyse mRNA from various sources, cDNA libraries, a genomic 
library and restriction endonuclease digested DNA. py/,~/ , K v (tt 5,' ~ 
G 
Thus, a number of recombinant DNA techniques were employed 
primarily to obtain cDNA or genomic clones which contain 
mammalian LH-RH decapeptide encoding sequences. A second 
objective was to determine whether genes related to the mammalian 
LH-RH encoding gene occur in man. A final objective was to 
investigate LH-RH gene expression in the ovariectomized -
estradiol replaced rat model for investigating the hypothalamo-
hypophyseal-gonadal axis. This model was thought to be most 
likely to demonstrate changes in hypothalamic LH-RH precursor 
mRNA levels (previously unmeasurable) because of the exaggerated 
serum LB-levels observed after ovariectomy and the marked 
reversal to levels within the normal range for intact animals 
after estradiol replacement. 
In order to enrich for the rat LH-RH encoding mRNA prior to 
cDNA cloning, several fractionation procedures were used. 
Membrane bound polysomes from rat and sheep hypothalami were 
shown to have higher amounts of LH-RH-IR associated with them 
than free polysomes, and were thus used as an enriched LH-RH mRNA 
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source. mRNA from rat and sheep hypothalami as well as from the 
HEp-3 human buccal cell line were size fractionated on sucrose 
density gradients and certain fractions were shown to be enriched 
for LH-RH encoding mRNA by dot-blot hybridization to 
oligonucleotide probes for LH-RH N- and C-terminus encoding 
sequences. Poly A mRNA was size fractionated by electrophoresis 
on methyl mercury hydroxide containing agarose gels and RNA 
extracted from gel slices was analysed by dot-blot analysis as 
well as by translation and immunoprecipitation in the Xenopus 
oocyte system. cDNA libraries made from these enriched sources 
of LH-RH mRNA were analysed by colony hybridization, plasmid 
isolation, cDNA insert excision and Southern blot hybridization. 
Sequence analysis of positively hybridising cDNAs from all these 
"enriched libraries" failed to reveal sequences which encode the 
LH-RH decapeptide. For the purpose of simplicity, none of the 
techniques employed or the results obtained in the course of 
these inconclusive investigations is presented here. 
During the course of these studies the nature of the 
mammalian LH-RH precursor was elucidated from the sequence of 
cloned human placental and hypothalamic cDNA, rat hypothalamic 
• 
~ cDNA and mouse genomic DNA. Probe L 11 (Table 4.8) which 
represents the longest stretch of sequence homology shared by 
•• these clones was used as a primer to construct an enriched 
library from rat pre-optic area poly A RNA. cDNA clones were 
••• obtained. which extended beyond the 5' end described in the 
published rat hypothalamic LH-RH cDNA sequence. Together with 
direct primer extension studies, the new sequence information 
obtained from these clones pin-pointed the 5' end of rat 
hypothalamic LH-RH mRNA. The primer extension studies together 
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with an examination of the human placental LH-RH cDNA sequence 
provided substantial evidence for the existence of two 
transcription iniatil n sites within the LH-RH gene. Together ( 
~ 
with the fact that the 1st intron ·of the LH-RH gene is not 
removed ins me instances of mRNA maturation (e.g. in the 
t . 
placenta ~ these observations have indicated the possibility of 
four mature mRNAs of differing length being transcribed from the 
LH-RH gene. Support for this possibility was supplied by 
northern blot hybridization results using sheep and rat 
hypothalamic poly A mRNA, as well as by primer extension studies 
using poly A RNA from the preoptic area of rat hypothalami, human 
hypothalami and two human breast tumour cell lines. 
Southern blot hybridization studies using the unique probe 
LlO (Table 4.7) indicated that two other genes with sequences 
related to the GAP (GnRH Associated Peptide) N-terminus may be 
present in man. 
In situ hybridization studies using a rat hypothalamic LH-RH 
precursor complementary-RNA probe and LR-RH-precursor mRNA 
quantitation by Sl nuclease assay using probe Lll, support the 
concept of "reciprocal regulation" of LH-RH gene transcription 
relative to pituitary LH release in the ovariectomized-estradiol 
replaced rat model. 
5.2 cDNA Cloning and Analysis of Transcription Start Sites 
5.2.1 Methods 
5.2.1.1 mRNA Isolation 
RNA from the preoptic areas of rat hypothalami was extracted 
by the single step RNA procedure (Chomczynski and Sacchi, 1987). 
5 g of frozen rat hypothalamic preoptic area were homogenised 
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with an Ultra Turrax homogeniser in 14 ml of 4 M Guanidinium 
Thiocyanate, 25 mM Sodium Citrate (pH 7.0), 0.5% Sarcosyl and 0.1 
M beta-Mercaptoethanol (Solution D). 1.4 ml of 2 N NaOAC (pH 
4.0) was added to the homogenate and mixed thoroughly, followed 
by 14 ml of H2o saturated phenol and 2.8 ml of CHCl3 : 
isoamylalcohol (49:1). The solution was mixed vigorously for 10 
seconds, incubated on ice for 15 minutes and centrifuged at 10 
000 g for 20 minutes at 4°c. RNA was precipitated from the 
aqueous phase by addition of one volume of isopropanol followed 
by centrifugation at 10,000 g for 20 minutes at 4°c. The RNA 
pellet was resuspended in 5 ml of solution D, reprecipitated with 
isopropanol, washed with 75% ethanol at room temperature, dried 
by evacuation and resuspended in binding buffer for application 
to an oligo dT cellulose column. An aliquot was removed for 
quantitation by monitoring the on260 ;on280 ratio. 
5.2.1.2 Poly A mRNA Preparation 
Poly A RNA was prepared on oligo dT cellulose chromatography 
by a modification of the method of Pelham (Pelham and Jackson, 
1976). 7 mg of total RNA at a concentration of 1 mg/ml in 
binding buffer (10 mM Tris/HCl (pH 7.5), 0.5 M NaCl, 0.05% SDS) 
was heated to 65°c for 5 minutes and applied directly to 2 ml 
(packed bed volume) of oligo dT cellulose (pre-equilibrated in 
binding buffer) mixed thoroughly and allowed to cool to room 
temperature. The resin was packed into a 5 ml syringe and the 
effluent re-applied to the column three times. The column was 
washed with 40 ml of binding buffer at a flow rate of N0.2 
ml/min. The poly A RNA was eluted by 10 applications of 400 ul 
of elution buffer (10 mM Tris/HCl (pH 7.5), 0.05% SDS). Poly A 
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RNA was pelleted from the 10 fractions by addition of 50 ul of 3 
M NaOAC (pH 7.0) and 450 ul of isopropanol, incubation on crushed 
dry ice for 10 minutes and centrifugation at 10 000 g at 4°c for 
20 minutes. Pellets were washed with 75% ethanol and evacuated 
dry. 
5.2.1.3 cDNA Cloning 
10 ug of Rat Preoptic Area poly A RNA was heat denatured in 
distilled water (dH 20) at 65°c for 3 minutes and placed directly 
on ice. The RNA was reverse transcribed in a 100 ul reaction in 
a mixture containing 50 mM Tris/HCl (pH 8.2), 140 mM KCl, 8 mM 
MgC1 2 , 500 uM each dNTP, 20 units of Human Placental Ribonuclease 
Inhibitor and 20 units of Avian Myeloblastoma Virus Reverse 
Transcriptase in the presence of either 100 ng of oligonucleotide 
L11 or 2.5 ug of Oligo d(T) 12-18. The cDNA cloning strategy 
employed is outlined in Fig. 5.1. 
a) Specific first strand synthesis 
The oligonucleotide Ll1 primed reaction was incubated for 30 
minutes at 42°c, heated to 65°c for 3 minutes, placed on ice for 
3 minutes, 20 units of AMV Reverse Transcriptase added and the 
reaction repeated for 30 minutes at 42°c. This procedure was 
repeated ten times in order to increase the amount of specific 
primer extended cDNA. Second strand synthesis was performed by 
diluting the first strand reaction mix to 200 ul and adding DTT 
to 5 mM, 50 units of E. coli DNA polymerase 1, and 2 units of E. 
coli RNase H. After a 2 h incubation at 16°c, the reaction was 
terminated with 12 uM EDTA (pH 8.0), phenol: chloroform 
extracted and ethanol precipitated from 0.5 M ammonium acetate. 
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b ) Selected second strand synthesis 
After first strand synthesis, the oligo-d(T) 12-18 primed 
reaction mixture was used to resuspend the double stranded DNA 
pellet from the oligonucleotide Ll~ initiated synthesis. The 
second strand from the latter reaction was then used as a 
selective primer for 2nd strand synthesis off the oligo dT primed 
cDNA. 
The reaction mixture was boiled for 3 minutes, chilled on 
ice, centrifuged for 3 minutes in a microcentrifuge and the 
supernatant transferred to a new tube. 5 ug of DNase-free RNase 
was added to the tube together with dNTPs to a final 
concentration of 200 uM and 80 units of reverse transcriptase. 
After incubation at 42°c for 2 h, the reaction volume was doubled 
and a further 20 units of reverse transcriptase and 10 units of 
DNA polymerase I large fragment were added. Second strand 
synthesis was continued for 1 hat 37°c and after the addition of 
a further 10 units of DNA polymerase I large fragment, for a 
further 4 hat 1s0 c. The reaction was stopped with 12 uM EDTA 
(pH 8.0), phenol : chloroform extracted and ethanol precipitated 
from 0.3 M NaOAc. 
c) Restriction endonuclease selection of cDNA inserts 
A BamHI restriction endonuclease site is present in a part 
of the rat hypothalamic LH-RH precursor cDNA representing the 3' 
untranslated region of the mRNA. This information was used for 
further enrichment of LH-RH precursor cDNA clones in the library. 
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The ethanol precipitated ds cDNA was thus redissolved in 
dH 2o and digested with 40 units of BamHI enzyme in the 
appropriate buffer for 2 hat 37°c. 
After organic solvent extraction and ethanol precipitation 
the DNA larger than 250 bases was size selected on a 4% 
acrylamide gel run in TBE buffer (1 x TBE = 89 mM Tris, 89 mM 
Boric Acid, 2 mM EDTA) DNA was retrieved from the gel slice by 
electrophoresis onto a DEAE membrane also in TBE buffer. The DNA 
was eluted from the membrane by boiling in 500 ul of TE. 
100 ng of BamHI, Sal! cut pGem vector DNA was added to the 
dsDNA and precipitated from 0.3N NaOAc with one volume of 
isopropanol. The ethanol washed pellet was redissolved in 20 ul 
of 50 mM Tris/HCl (pH 7.8), 10 mM MgCl2, 20 mM DTT and 1 mM ATP. 
5 Units of T4 DNA ligase was added and the reaction incubated at 
15°c for 18h. 
d) Transformation of E. coli 
E. coli K-12 strain (HB 101) were grown to 0.5 00 600 units 
in 20 ml of L-broth (1% Bacto-tryptone, 1% NaCl, 0.5% Bacto-yeast 
extract). After centrifugation at 3 000 g for 5 minutes, the 
bacterial pellet was resuspended in 10 ml of 10 mM Tris/HCl (pH 
7.3) containing 50 mM CaC1 2 and repelleted at 4°c. The bacteria 
were resuspended in 2 ml of the above buffer and incubated at 4°c 
for 5 minutes. To 200 ul of this suspension was added 20 ul of 
recombinant pGem in ligation buffer. The bacterial suspension 
was kept at 4°c for 40 minutes followed by 42°c for 2 minutes. 
0.5 ml of L broth was added to the suspension and incubated at 
37°c for 30 minutes. 25 ul aliquots were spread on L-agar plates 
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containing 40 ug/ml of ampicillin and bacterial growth allowed to 
proceed for 18 hat 37°c. 
e) Colony hybridization 
-3 x 10 4 recombinant colonies were transferred to duplicate 
nylon filters from agar plates. The filters were placed on 
Whatman 3M paper saturated with 0.5 N NaOH and 1.5 M NaCl for 5 
minutes. The filters were tranferred to 3M paper saturated with 
1.5 M NaCl, 0.5 M Tris/HCl (pH 8.0) for neutralization. The 
neutralization step was repeated twice and the filters were air 
dried. DNA was fixed to the filters by exposure to ultra-violet 
light for 2 minutes. The filters were prewashed at 56°c for 5 h 
in a solution of 0.3 M NaCl, 0.03 M sodium citrate, and 1% SDS. 
Prehybridization was performed at 56°c for 2 h in 6 X SSC (1 X 
SSC= 0.15 M NaCl, 0.015 M sodium citrate), 0.25% skim milk 
powder, 0.06% NaPPi, 1% SDS and 100 ug/ml sonicated salmon sperm 
DNA. Oligonucleotide Lll was labelled to a specific activity of 
10 7 cpm/pmole with 10 units T4 polynucleotide kinase using 100 
uCi of [gamma- 32P]-ATP (5 000 Ci/mmole) in 10 ul of 50 mM 
Tris/HCl (pH 7.4), 10 mM MgC1 2 , 5 mM DTT and 0.1 mM spermidine. 
The labelled oligonucleotide was separated from free ATP on a G-
25 spin column in 100 ul of TE. 50 ul of labelled 
oligonucleotide was heated to 65°c for 3 minutes and added 
directly to the prehybridization solution. Hybridization was 
allowed to proceed at 55°c for 18 h. The filters were washed 3 
times for 30 minutes each in 0.2 X SSC, 0.06% NaPPi, 1% SDS at 
55°c, allowed to air dry and subjected to autoradiography at -
70°c in the presence of Cronex amplifying screens. 
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f) Plasmid minipreparations 
Colonies which hybridized to probe Lll were picked off the 
original plate and grown in 40 ml of L broth overnight. Plasmid 
DNA was prepared by the alkaline extraction method (Birnboim and 
Doly, 1979). The cDNA inserts were removed from the plasmids by 
digestion with the enzymes EcoRI and BamHI. The cleaved DNA was 
electrophoresed on a 0.8% agarose gel in 1 X TBE. The DNA was 
visualized by fluorescence under UV irradiation after staining 
with 0.5 ug/ml ethidium bromide aqueous solution. The DNA was 
denatured in the gel by soaking in 1.5 NaCl, 0.5 M NaOH for 1 h. 
The gel was neutralized by soaking for 1 h in 1.5 M NaCl, 1 M 
Tris/HCl (pH 8.0). The DNA was transferred to nylon filters by 
the Southern blotting technique (Southern, 1975). The filters 
were UV fixed and prehybridization and hybridization performed as 
outlined above for colonies. 
g) Supercoiled DNA sequencing 
The plasmid DNA with the longest insert that hybridized to 
oligonucleotide Lll was purified for sequencing by dissolving the 
minipreparation DNA from 20 ml of liquid culture in 160 ul of 
H2o, adding 40 ul of 4 M NaCl, 200 ul of 13 polyethylene glycol 
(MW 8 000), mixing well and incubating at 4°c for 30 minutes. 
Supercoiled DNA was selectively pelleted by microcentrifugation 
at 4°c for 20 minutes. The pellet was washed in 70% ethanol, 
dried and redissolved in sterile water at a concentration of 1 
ug/ul. 
2 ug of supercoiled DNA was denatured in the presence of 30 
ng of oligonucleotide primer (pGEM-3, T7 promoter primer or SP6 
promoter primer) by incubating in 20 ul of 0.2 N NaOH, 0.2 mM 
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disodium EDTA for 5 minutes at room temperature. NaOAc was added 
to 0.3N and the DNA precipitated by incubation at -20°c after the 
addition of 2.5 volumes of ethanol. After microcentrifugation 
and washing in 70% ethanol the DNA pellet was dissolved in 9 ul 
of sterile water. To this was added 1 ul of reverse 
transcriptase buffer (340 mM Tris/HCl pH 8.3, 500 mM NaCl, 60 mM 
Mg c1 2 , 50 mM DTT), 1 ul of reverse transcriptase (20 units) and 
4 ul of [alpha-32P]-dATP (10 mCi/ml, >400 Ci/mmole). 
To 3 ul of each of the specific nucleotide mixes (G, A, Tor 
C), each containing nucleotides and the appropriate 
dideoxynucleotide at the concentrations described by Zagurski et 
al. (Zagurski et al., 1985) was added 2.8 ul of the primer/ 
template/enzyme/label mixture and transcription performed at 
42°c for 10 minutes. The reactions were stopped by adding 5 ul 
of 90% formamide containing 20 mM EDTA, 0.3% bromophenol blue and 
0.3% xylene cyanol. 2 ul of each chain-termination sequence 
reaction was heated to 70°c for 3 minutes and loaded directly 
onto a pre-electrophoresed 6.6% sequencing gel (6.6% 
polyacrylamide, 50% urea, 1 x TBE) and run at 1500 - 2000 volts. 
A second gel loading was performed when the xylene cyanol from 
the first loading reached the bottom of the gel. The gel run was 
terminated when the bromophenol blue of the second loading 
reached the bottom of the gel. Runs of this nature were 
sufficient to deduce 250-350 bases of sequence. 
5.2.1.4. Primer Extension 
Oligonucleotide Lll was labelled to a specific activity of 
-10 9 cpm/ug with T4 polynucleotide kinase. 40 ng of labelled 
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~ SPECIFIC SECOND 
~ BAM HI 
' SIZE SELECT 
' LIGATE TO PLASMID 
' TRANSFORM BACTERIA 
Fig. 5.1 SPECIFIC FIRST AND SECOND STRAND SYNTHESIS PROTOCOL FOR 
A RAT PREOPTIC AREA cDNA LIBRARY ENRICHED FOR THE LH-RH 
PRECURSOR cDNA. 
Oligonucleotide Lll was used as a specific primer for 
LH-RH precursor cDNA synthesis. After 2nd strand 
synthesis, hybridization to full length 1st strands was 
carried out and specific ful 1 length 2nd strands were 
synthesized. The cDNA was size selected and 
directionally cloned into the pGem vector. 
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mM Tris/HCl (pH 8.0), 8 mM MgC1 2 , 50 mM KCl, 4 mM DTT and slowly 
cooled to 55°c. The annealed primer and RNA were precipitated 
with one tenth volume of 3mM NaOAc and one volume of isopropanol, 
then resuspended in the same buffer containing dNTPs, at a final 
concentration of 500 uM each in a final volume of 20 ul. Ten 
units of reverse transcriptase were added and the reaction 
allowed to proceed for 30 min at 42°c. After phenol-chloroform 
extraction and ethanol precipitation the extension products were 
analysed on 0.8% agarose alkaline gels or on 8% denaturing 
acrylamide gels. The alkaline gels were dried down prior to 
autoradiography while the acrylamide gels were autoradiographed 
directly. 
5.2.1.5 Northern Blotting and Hybridization 
20 ug of rat or sheep poly A RNA was run on 1.5% Agarose 
gels containing 2.2 M Formaldehyde 50 mM Morpholinopropane-
sulphonic acid (MOPS) (pH 7.0), 10 mM NaOAc and 1 mM EDTA. Dry 
RNA pellets were reconstituted in the same buffer used for 
casting the gel but containing 50% Formamide. The dissolved RNA 
was heated to 55°c for 15 min. 2 ul of 50% glycerol, lmM EDTA, 
0.4% Bromophenol Blue, 0.4% Xylene Cyanol was added and the RNA 
loaded onto the gel and electrophoresed overnight at 30 Vin gel 
casting buffer without formaldehyde. Prokaryotic and eukaryotic 
ribosomal RNAs were used as molecular weight markers and 
visualized on a UV box after staining with 0.5 ug/ml ethidium 
bromide in 0.1 M beta-mercapto ethanol. RNA was transferred out 
of the gel onto a nylon membrane by overnight capillary transfer 
as for Southern Blots, and fixed to the membrane by UV 
irradiation for 5 min. Prehybridization was performed at 42°c in 
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6 x SSC, 0.25% skim milk powder, 0.5% SDS 0.06% NaPPi, 5 mM EDTA 
(pH 8.0), 100 ug/ml sonicated salmon sperm DNA and 100 ug/ml 
yeast transfer RNA. Oligonucleotide probes Ll and L9 labelled to 
a specific activity of 108 cpm per pmole were added to the 
prehybridization solution after heating at 65°c for 3 min. 
Hybridization was allowed to proceed at 42°c for 18 hours. Three 
10 min washes in 4 x SSC, 0.06% NaPPi, 0.5% SDS were performed at 
42°c and the filters subjected to autoradiography at -70°c in the 
presence of Cronex amplifying screens. 
5.2.2 Results and Discussion 
The single step RNA purification protocol proved to be very 
effective in obtaining high yields of intact RNA free of protein 
and DNA. Yields of 1.4 ug total RNA/mg tissue (wet weight) with 
OD250/0D 280 ratios of >2.0 were achieved. Thus from 5 g of rat 
pre-optic area 7 mg of total RNA was obtained. 
After oligo dT chromatography -100 ug of poly A RNA was 
obtained from the 7 mg of total RNA applied. First strand cDNA 
synthesis using oligonucleotide Lll gave a predominant product of 
-125 bases (Fig. 5.3) while the predominant range of oligo d(T) 
12-18 primed cDNA was between 1.6 and 2.2 Kb which coincides with 
the average length of eukaryotic mRNA. 
The second strand synthesis on the long cDNA template using 
the denatured specific second-strand as primer, together with the 
restriction enzyme selection of inserts, proved to be an 
effective protocol for the rare LH-RH precursor mRNA. Thus, of 
the 3 x 10 4 clones screened, 38 hybridized to oligonucleotide 
Lll. Of the 20 minipreparations tested 18 had inserts of -340 
bases long, the remaining 2 being only marginally shorter. 
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Fig. 5. 2 CHAIN TERMINATION SEQUENCING OF DENATURED SUPERCOILED 
DNA. 
T7 RNA polymerase primer was used to sequence a cDNA 
insert from the enriched rat pre-optic area library by 
the protocol outlined in Fig. 5.1. The insert 
hybridized to probe Lll. The sequence indicated on the 
right is that of the LH-RH decapeptide. The cDNA 
sequence extended 6 bases beyond the pub 1 ished 5 ' -end 
of the message. The success of the method employed was 
evidenced by the fact that the insert was extended 
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El..g_~· o.3 L11 PRIMER - EXTENSION USING POLY-A RNA FROM 
HYPOTHALAMI AND BREAST TUMOUR CELL LINES AS TEMPLATE 
10 µg of poly-A RNA from rat pre-optic area (R), human 
hypothalamus (H), or two breast tumour cell lines, MDA-
MB-231 (M) , and ZR-75-1 (Z) were reverse transcribed 
using 5'-end labelled oligonucleotide Lll. A 125-base 
product was produced from RNA from all tissues. Longer 
transcripts were also obtained in each tract. Fig. 5.J (b) 




Double stranded sequencing of one of the clones by the 
method of Zagurski et al., showed that it was identical to the ~ 
/{/1/1 e>td pU{..,_ 
rat hypothalamic cDNA described by Adelman et al., except for / the 
extension of six bases at the 5' end, viz. 5'GAAGAT- (Fig. 5.2, 
Fig. 5.4Cl). The first three bases at the 5' end conform to a 
typical "cap" or transcription start site i.e. Pyr-A-Pyr (Fig. 
5. t a). If this is indeed the transcription initiation site used 
by RNA polymerase II an AT-rich TATA box would be expected 25-35 
bases upstream (Goldberg, 1979; Shenk, 1981). Since the 
upstream region of the ~ -RH gene has been sequenced in the human 
placental LH-RH precursor cDNA (Seeburg and Adelman, 1984) and in 
the mouse (Mason et al., 1986), the published sequences were 
examined for this and other typical promoter elements. In the 
case of the human (as reflected in the placental mRNA sequence) 
the typical TATAA sequence occurs between bases -50 to -55 
relative to the proposed cap site (Fig. 5.4 a). In the mouse gene 
this sequence occurs between positions -47 to -51 relative to the 
proposed initiation point. Since this TATA box is relatively 
far upstream from the CAP site, primer extension studies were 
performed using poly A RNA from human and rat hypothalamus and 
from the human breast tumour cell lines MDA-MB-231 and ZR-75-1 
(Fig. 5.3). The major primer extended product from all. four 
tissues ran at a position of 125 bases on alkaline agarose gels 
and on 8% acrylamide sequencing gels. This coincides exactly 
with the 5' terminal sequence of the cDNA clone described above. 
Since the reverse transcriptase catalysed reaction was performed 
after heat denaturation and in the presence of high 
concentrations of dNTPs (500 uM each), the primer extension 
probably went to completion. Also, since a longer primer 
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Fig. 5. ~ EVIDENCE FOR TWO TRANSCRIPTION START SITES IN THE LH-RH 
GENE. 
The sizes of the primer extended cDNAs are consistent 
with two transcription start sites in the gene. The 5' 
region of the untranslated human placental LH-RH cDNA 
includes an intron transcript as evidenced from the 
sequencing of rat and human hypothalamic mRNAs. The 
two start sites and the possible inclusion of the 
intron transcript makes possible the existence of 4 LH-
RH mRNAs in certain tissues, e.g. in the breast tumour 
cell line ZR-75-1. 
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extension transcript is observed in all four cases, it is 
unlikely that this sequence repr~sents a premature stoppage point 
for the enzyme. 
Although the 5' end or cap site of mRNA is generally 
believed to represent the transcription initiation site of a 
gene, there is evidence for some primary transcripts being 
cleaved or degraded at the 5' terminus and the resultant newly 
exposed 5' ends being capped (Shenk, 1981). Vaccinia cores have 
been shown to contain a 5' phosphate-phosphoribonucleotide kinase 
which facilitates such a restriction by converting the 5'-
terminal monophosphate resulting from degradation to a 5'-
terminal triphosphate (Spencer et al., 1978). RNA degradation 
l 
studes have demonstrated specific RNA endonucleases and 5' to 3' 
exonucleases in nuclei (Furuichi et al., 1977) as well as 5' 
termini particularly susceptible to degradation (Piechaczyk et 
al., 1985; Rabbits et al., 1985). Multiple early cap sites have 
been shown in the SV40 genome (Reddy et al., 1979; Thompson et 
al., 1979; Haegeman and Fiers, 1980), other viral genes (Soeda 
et al., 1980; Baker and Ziff, 1981) as well as the sea urchin 
H2A gene (Hentschel et al., 1980). There is also a distinct 
hierachy of cap site preferences: A>G>>U>C (Baker and Ziff, 
1981). One could thus propose that transcription beginning at a 
particular initi~tion site could give rise to a primary 
transcript with a poor capping site and/or a labile 5' terminus 
which is rapidly degraded to expose a better and/or more stable 
capping site. This could be a possible reason for the longest 
primer extended products in this study ending -so bases 
downstream and not 25-35 bases downstream from the proposed TATA 
box. 
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Examination of the human placental LH-RH cDNA sequence 
around the proposed transcription initiation site in the gene 
reveals a number of features characteristic of DNA binding sites 
for transcription factors that can distinguish between certain 
genes (for reviews see Serfling et al., 1985; McKnight and 
Tjian, 1986; Maniatis et al., 1987). 
Firstly, three potential enhancer core elements related to 
the SV40 enhancer elements (Herr and Clarke, 1986) and other 
viral enhancers (Gruss, 1984) (Fig. 5.4-b) occur in close proximity 
to or incorporate: 
a) The proposed CAAT box; 
b) The proposed TATAA box; 
c) The proposed transcription initiation site. (Fig 0;4,(a)), 
Secondly, two sequences with a strong resemblance to the 
octameric enhancer elements of the immu~oglobulins, chicken 
histone 2B, Xenopus U2 and SV40 genes (Herr et al., 1986) are 
also in close juxtaposition to the CAAT box and transcription 
,start site proposed here for the LH-RH gene (Fig. 5.+c). 
Thirdly, an inverted repeat of a pentanucleotide 
incorporating the proposed CAAT box, viz. 5' ATTGA 3', occurs 
immediately downstream from the proposed CAP site (Fig. 5.+a), 
The family of NF-Y proteins has been shown to bind CAAT box 
pentanucleotides in the reverse orientation in a number of genes. 
These include all class II major histocompatibility genes, the 
herpes simplex thymidine kinase gene, human alpha- and beta-
globin genes and the Moloney sarcoma virus LTR genes (Dorn et 
al., 1987 (a), 1987 (b)). The existence of these well 
characterized enhancer and promoter consensus sequences in close 
apposition to the proposed transcription initiation site could 
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be advanced as another reason for the relatively long distance 
between the TATAA box and the proposed transcription initiation 
site. The binding of proteins to the proposed enhancer core 
elements, the octameric sequences and the reverse CAAT box 
sequence in the gene could conceivably prevent RNA polymerase II 
from beginning transcription at the usual positions 25-35 bases 
downstream from the TATAA box. Whether these previously 
described DNA-binding proteins bind to the LH-RH gene at these 
points and whether the proposed "crowding" results in 
0., 
transcription initiation at position -so bases downstream from 
(\ 
the TATAA box, deserves further investigation. 
An inverted repeat sequence, suggestive of partial two fold 
symmetry occurs at the proposed start site of transcription, viz. 
-9CTT-6c and - 1GAA+3G (ie. positions -9 to +3). Similar regions 
of partial or "hyphenated" two-fold symmetry have been described 
in the vicinity of transcription start sites of a number of genes 
including the adenovirus Ela gene (-11 to +9), the mouse beta-
globin gene (-17 to-2) and the chicken ovalbumin gene (-7 to +7) 
(Ganon et al., 1979). Whether this partial two fold symmetry 
facilitates transcription initiation by RNA polymerase II at this 
particular site in the LH-RH gene also deserves further 
investigation. 
Footprinting, in vitro transcription, and transfection 
studies using deletion and point mutations in this region of the 
LH-RH gene are necessary to validate the above contentions 
inferred from the human DNA sequence. The three enhancer 
elements described here and which are similar to the SV40 
enhancer core elements are similar to elements in the 
irnrnunoglobulin heavy chain gene. The relevant irnrnunoglobulin 
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heavy chain enhancer operates much less efficiently in 
fibroblasts than in lymphoid cells suggesting a tissue specific 
role for this element. Recently, certain RNA polymerase III 
transcripts, believed to arise from introns in postnatal-onset 
neuronal-specific genes and in certain immortalized rodent cell 
line genes have been proposed as enhancers of RNA polymerase II 
gene expression (McKinnon et al., 1986). A consensus enhancer 
sequence GTGGTAG in the so-called A-box of the RNA polymerase III 
promoter is similar to the typical enhancer elements described in 
Fig. 5.4 . It is believed that RNA polymerase III transcription 
of neuronal ''identifier" sequences may facilitate expression of 
neuron-specific RNA Polymerase II transcription units (McKinnon 
et al., 1986). The transcription unit described here for the LH-
RH gene complies with this proposed model of synchronous positive 
regulation of neurone specific genes. 
Since the placental LH-RH precursor mRNA extends further 
upstream from the transcription initiation site proposed here, 
another transcription initiation site must occur in the gene. 
The primer extension studies showed that both these initiation 
sites are used in the hypothalamus and in the breast tumour cell 
lines. 
In the hypothalamus, transcripts of the 1st intron are 
I 
always excised while this isn't the case in the breast tumour 
cell lines. In the case of the human hypothalamus, the longer 
primer extended product (450 bases) indicates that the first 
initiation site is -325 bases upstream from the one proposed here 
(Fig. 5.3). Examination of the gene sequence at this point will 
be necessary to confirm this site. In the case of the rat gene, 
the upstream transcription initiation site , as interpreted from 
84 
the longer (-600 bases) primer extended product
1
is -475 bases 
from the start site described here. Northern blot hybridization 
studies using 20 ug of rat hypothalamic poly A RNA per tract and 
wi th probes Ll and L9 revealed two bands representing RNA 
molecules of -soo bases and -1000 bases (Fig. 5.5). This further 
supported the interpretation of the primer extension experiments 
being due to the existence of two transcripti on initiation sites 
i n the LH-RH gene at the positions described above (Fig 5.3). 
Since the sequence representing the first intron in the gene 
i s sometimes not removed from the mature RNA, the existence of 
two transcription initiation sites in the gene provides the 
possibility for four possible mRNA species of differing length 
result from the same gene. In the case of the breast tumour cell 
l i ne MDA-MD-231 the smeared band between -1000 bases and -1325 
bases could be due to the use of both transcription initiation 
sites and the inclusion of the first intron sequences in the 
mature mRNAs. The broader smear in the case of the cell line ZR-
75-1 could be due to both transcription initiation sites being 
used and the intron being spliced out or left in, i.e. due to all 
4 messages being present. All attempts to improve the resolution 
of these bands were unsuccessful. Examination of the placental 
LH-RH precursor mRNA for inverted repeat sequences revealed the 
presence of 19 such stretches of 8 bases or longer while only two 
such repeats occur in the shorter hypothalamic LH-RH precursor 
mRNA sequences. The potential for secondary structure and thus 
multiple reverse transcriptase stoppage points in the longer mRNA 
molecules presents a probable explanation for the smearing 
observed in the alkaline agarose gel tracts of the two breast 
tumour cell line primer extended products. 
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5 · AGGGCTTTATGTGAGGAIIIIIAAAAAATTACCATTAAAAAAAAAAAAGCATAGTCCATTTGCA 
-103 -74 -51 
GTATATAATTTACCAGCAGGAAAGATTT~_l.ATGTCCTGGAAAAATTCCC~ATAAAAAGGAAGAT 
OCTAMER._ 
-41 -10 -5 +l +4 +8 +26 
AGGAAAACAGA.8.~AGTCACA§TACTCAACCTACTTCAAGGGAAGATTGATCT 1111 GGCTCTCT 
OCTA.ME£~- TAACT 
+27 +37 
GCCTCTAACAGA ... 3' 
INTRON 1 
(a) Human Placental LH-RH cDN~ 5' end 
SV 40 Enhancer Elements 







5' GTGGAATGTG 3' 
GCAGAAGTAT 
GTGGAAAGTC 
-89 CAGGAAAGAT -ao 
-:51 AAAGGAAGAT -42 
-=s AAGGGAAGAT +=s 
Cb) Co_mparison _of SV 40 __ early__retgion _promoter enhan.cer _elements 
with LH-RH __ g_ene _ sequences in the rEtq_ion of a __ jlostulated 
trancription start site. 
SV 40 Octameric Control Element 1. 
2. 
LH-RH Octameric Sequence 1. 
2. 
5" A-TGCAAAT 3" 
A-TGCAAAG 
- 01 ATTTCAA-T - 74 
- 10 ACTTCAA-G - 3 
Cc) Co...mp risen of octameric enhancer elements in the SV 40_g_enome 
with segJ,,U:mce~_i_o_ the v;ici ni ty of a proposed l,.H-RH gene 
promoter. 
Fig. 5 . .lj- A PUTATIVE PROMOTOR UNIT FOR THE HUMAN LH-RH GENE. 
(a) Rat preoptic area LH-RH cDNA sequence and primer extension 
studies using rat and human RNA indicate that transcription is 
probably initiated at position +1 in the r~t and human LH-RH 
genes. Potential enhancer repeat sequences are highlighted or 
underlined in the case of the octameric element. The CAAT and 
TATAA box promotor elements as we 11 as other potential cap 
sites are underlined. The underlined sequence CTTC at 
positions -6 to -9 is an inverted repeat of GAAG at positions 
+l to +4. The reverse CAAT box at position +4 is indicated by 
the sequence of the complementary strand beneath it. 
(b) and (c) show. that there is substantial sequence homology 
between these enhancer elements and the we 11 characterised 
SV40 enhancer sequences. 
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The potential for secondary structure within the mRNA 
representing the first intron of the gene presents the intriguing 
possibility of the regulation of translation rates at the level 
of splicing. A precedent for this type of translation inhibition 
by "antisense" secondary structure at the 5' end of the mRNA is 
in the case of the c-myc oncogene where exon I - exon II 
hybridisation is believed to result in a low rate of translation. 
Translocation or rearrangement of the gene at these positions 
results in high levels of the c-myc protein with resultant 
transformation, e.g. Non-Hodgkins lymphoma and murine 
plasmocytomas (Piechaczyk et al., 1985; Rabbits et al., 1985). 
Added to this possibility of LH-RH mRNA translation 
inhibition by including the 1st intron in the mature message is 
the possible inhibition by antisense RNA arising from 
transcription of the other DNA strand of the gene, as proposed by 
Adelman et al. (Adelman et al., 1987). Such inhibition has been 
demonstrated in. a number of prokaryotic systems (Green et al., 
1986) and enzymes which specifically unwind RNA hybrids have been 
shown in Xenopus oocytes (Bass et al., 1987; Rebagliati et al., 
1987). 
LH-RH gene expression studies thus provide an ideal system 
for investigating whether regulation at the level of RNA-RNA 
interaction occurs in eukaryotes as well. 
Another possibility presented by the existence of two 
transcription initiation sites in a gene is the existence of 
another translation start codon between the transcription start 
sites. Whether such an in-frame ATG codon exists in the as yet 
87 
S R 




Fig. 5 .5. NORTHERN BLOT ANALYSIS OF 10µG OF RAT PREOPTIC AREA 
POLY-A RNA AND SHEEP HYPOTHALAMIC RNA 
The mixed probe Ll was used for hybridization. This 
mixture includes the correct sequence for the rat LH-RH 
gene. Two RNA species of ±500 and 900 bases were 
detected in the rat pre-optic area RNA while at least 
four were seen in the sheep RNA. These resu 1 ts are 
consistent with the interpretation of the primer 
extension studies and the observed inclusion of an 
intron transcript in some tissues, e.g. placenta and 
the breast tumour cell lines. 
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unsequenced 5' end of the LH-RH gene deserves investigation. 
This possibility is supported by the demonstration described in 
this thesis and by the work of other investigators, of proteins 
with LH-RH-IR and which are larger than the 10 000 daltons 
predicted by the only translation start codon demonstrated to 
date (Adelman et al., 1986; Millar et al., 1977; Curtis and 
Fink 1983a, 1983b). However, translating the 5' terminus of the 
human placental rnRNA to amino acids in all three reading frames 
results in termination of the hypothetical protein prior to the 
proposed transcription initiation site proposed here. Thus, one 
would have to invoke the argument of sequencing errors in the 
published sequence in order to persist with the proposal of a 
larger protein precursor being translated from the rnRNA 
transcribed from the upstream initiation site of the LH-RH gene. 
The rat aldolase A gene has been shown to have three 
transcription iniation sites resulting in three rnRNAs differing 
in the length of their 5' untranslated regions (Joh et al., 
1986). In the case of this gene, as well as in the mouse alpha 
amylase gene which has two transcription initiation sites, there 
are strong indications that the promotors for the different 
initiation sites are of different strengths and may have tissue 
specificity (Young et al., 1981; Joh et al., 1986; Breitbart et 
al., 1987). In the case of the LH-RH gene, the transcription 
start site described here appears to be driven by a stronger 
promotor than the upstream promotor, hence the more abundant 125 
base primer extended product in all tissues tested (Fig. 5.3). 
The demonstration of enhancer elements in close proximity to the 
proposed CAAT box lends further support to this interpretation of 
the primer extension studies. 
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That genes have multiple transcription start sites which 
result in m.RNAs differing in the length of the 5' untranslated 
region may be a ubiquitous phenomenon, is supported by the recent 
demonstration of this fact in the insulin-like growth factor I 
gene (Lowe et al., 1987) and the beta-TSH gene (Wolf et al., 
1987). 
Transcription initiation at heterogeneous sites in the gene 
can give rise to defective or untranslatable m.RNA. This is 
demonstrated in the case of the shorter POMC gene transcripts 
found in the testis which cannot give rise to the normal POMC 
peptides (Lacaze-Masmonteil et al., 1987). 
RNA "fusion" studies have shown that labile sequences having 
short half lives (e.g. the 3' untranslated region of the C-fos 
m.RNA) can decrease the stability of a stable mRNA when fused to 
the 5' terminus of the latter (e.g. the 5' untranslated region of 
the V-fos m.RNA) (Miller et al., 1984). 
Whether the longer LH-RH gene transcripts are defective, 
untranslatable or marginally translatable and whether RNA 
turnover is significantly different in the messages arising from 
the two transcription initiation sites is deserving of 
investigation. 
5.3 LH-RH Related Genes In Mammals 
5.3.1 Introduction 
Although conclusive evidence has been provided for the 
existence of multiple forms of LH-RH in other vertebrates (Millar 
and King, 1987), no peptide or gene sequencing data has been 
presented to establish this fact in mammals. Indeed Southern 
Blot studies by the group of Peter Seeburg have led them to 
90 
conclude that the LH-RH gene in the mammal is a single copy gene 
(Seeburg and Adelman, 1984; Adelman et al., 1986; Mason et al., 
1986). Furthermore, no support for cross hybridising genes has 
been forthcoming using the LH-RH precursor cDNAs as probes in 
these Southern blot studies (Adelman et al., 1986). 
It has to be borne in mind however, that the enkephalin 
precursor cDNA could not be detected with the pro-opiomelano-
cortin cDNA but by using oligonucleotide probes (Douglas et al., 
1984). The frog skin TRH precursor cDNA was also an unsuccessful 
probe for the mammalian cDNA since only the repeating TRH 
encoding units are conserved (Leehan et al., 1986). In the well 
characterized globin family of genes an alpha globin-like gene 
escaped detection for a number of years (Marks et al., 1986; 
Proudfoot, 1986). The cloned glycoprotein hormone beta-subunit 
cDNAs were also not suitable as probes for many of their related 
beta-subunit cDNAs. The reason for this is that the conserved 
sequences within a family of genes may be very small and there 
may even be divergence at the level of codon usage within the 
part of the gene conserved at the level of amino acid sequence. 
Thus, although the amino acid sequence of the LH-RH decapeptide 
is identical in rats and humans, there are 3 differences at the 
nucleotide level. Thus, the use of an oligonucleotide as a probe 
for related genes could also be fruitless if there has been 






5.3.2.1 Southern Blots see 5.2.1.3 (f) 
5.3.3 Results and Discussion 
Many restriction endonuclease generated human DNA fragments 
hybridised to the oligonucleotide probes used in this study after 
low stringency washes of Southern blots. However, many of these 
were due to non-specific hybridisation to satellite DNA bands. 
At high stringency, probes Ll and LlO hybridized to 
DNA band in the tracts of each of three restriction 
The size of this band was 11.5 Kb in the case of EcoRI digests, 
5.0 Kb in the case of BglII digests and 1.2 Kb in the case of 
PstI digests. These results coincide directly with the DNA 
fragments expected from the published data (Seeburg and Adelman, ;(. 
f ltr .d tu 
1984; Adelman et al., 1986). ..../ I U l,.to 
The only probe which consistently hybridized to more 't .J::::i. /'1J 7/,ru/, 
one restriction endonuclease generated fragment of human DNA 
under high stringency conditions, was probe LlO. This probe 
hybridized to at least three DNA fragments generated by each of 
three restriction enzymes (Fig. 5.6). Besides the 11.5 Kb EcoRI-
fragment known to contain the LH-RH encoding gene characterized 
by the Seeburg group, two other EcoRI fragments of 2.5 Kb and 570 
bases hybridized to this probe. In the case of the Bgl II 
digests DNA fragments of 5.0 Kb, 2.3 Kb and 1.6 Kb hybridized to 
this probe, while three fragments of 5.2 K.b, 1.8 Kb and 1.2 Kb 
were seen with Pst I digests (Fig. 5.6). Since washing of the 
Southern blots was carried out at the highest possible 
\\,{ M 
stringency, the other DNA fragments hybridizing to this unique '.~ 
(non-degenarate) probe are more than likely to contain sequences 
/'_.,----
related to the LH-RH prcursor encoding gene. This result is the 
--
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only positive indication to date of mammalian DNA sequences 
(reflecting other genes) which are related to the LH-RH precursor 
encoding gene. It should be noted that this probe did not 
hybridize to rat genomic DNA restriction endonuclease fragments 
under the hybridization conditions used. Examination of the rat 
LH-RH gene sequence corresponding to this probe revealed four 
base differences between it and the human gene at this locus, 
thus explaining this negative hybridization result. 
This probe (LlO) corresponds to amino acids 11-16 of the LH-
RH precursor which includes the processing site residues Gly11-
Lys- Arg13 . This sequence is probably shared by numerous 
precursor proteins and thus the nine out of eighteen bases at the 
3' end of probe LlO are likely to hybridize to a large number of 
genes. The Southern blot result obtained here could thus be 
partially explained by the expected high incidence of this 
sequence in the human genome. A search of the Genbank database 
for the entire sequence encoded by LlO did not reveal homology 
with other genes sequenced to date. However, in support of the 
existence of proteins related to the amino terminus of GAP, it 
was noted that there is remarkable sequence homology between 
amino acids 18-26 of the LH-RH precursor and amino acids near to 
the N-terminus of the inhibin family of polypeptides (Table 5.1). 
~.~ 
Since strong sequence homology exists between inhibin and 
~ 
beta-inhibin subunits and beta-TGF (Mason et al., 1985b) the 
homology indicated in Table 5.1 between the stretch of N-terminal 
amino acids in GAP and the inhibin/beta-TGF family of 
polypeptides, strongly suggests that the LH-RH precursor gene is 
related to this gene family. The Southern blot data presented 
here could be 
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Fig. 5.6 SOUTHERN BLOT OF RESTRICTION ENDONUCLEASE 
HUMAN DNA PROBED WITH OLIGONUCLEOTIDE L10 
DIGESTED 
Probe LlO is a complementary DNA oligonucleotide 
directed against the sequences encoding amino acids 11 
to 16 of the LH-RH precursor (Tab le 4. 7) . 30 1.1g of 
restriction enzyme digested DNA was run on an agarose 
gel and blotted onto nitrocellulose. 5'-end-labelled 
LlO was hybridized to 3 DNA fragments in every tract. 
These included an 11.5 Kb EcoRl (R) fragment, a 5.0 Kb 
Bgl I I (B) fragment, and a 1. 2 Kb Pstl (P) fragment as 
expected for the LH-RH encoding gene. The other 
fragments probably represent fragments of related 
genes. DNA sample I was from a normal subject while 
sample I I was from a person with Ka l lmann' s Syndrome 
and sample III from a patient with hypogonadism. There 
was no difference in the size of the LH-RH gene 
fragment or the other two hybridizing fragments for all 
three patients with the three enzymes used. 
H LH-RH 19 Leu Ile Asp Ser Phe Gln Glu Ile Val2" 
R LH-RH 18 Leu Val Asp Ser Phe Gln Glu Met Gly2" 
H ainhibin 235Leu Asn Ile Ser Phe Gln Glu Leu Gl y24:s 
H 8A Inhibin :z99Phe Phe Val Ser Phe Lys Asp Ile Gly:so• 
H 8e Inhibin 2•0Phe Phe Ile Asp Phe Arg Leu Ile Gly268 
H 8TGF :sooTyr Ile Asp Phe Arg Lys Asp Leu Gl y30• 
Table 5.1 SEQUENCE HOMOLOGY BETWEEN THE HUMAN (H) AND RAT (R) LHRH 
PRECURSOR AND INHIBIN / TGF FAMILY OF POLYPEPTIDES. 
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indicative of other members of this gene family, i.e. related to 
the N-terminus of GAP but not sequenced to date. 
Pro LH-RH 14-26 and pro LH-RH 17-37.NH2 have been shown to 
have LH- and FSH-releasing activity (Millar et al., 1986; Milton 
et al., 1987). 
~~~-
Inhibin beta-dimers inhibit FSH release from the 
~ 
pituitary (de Jong and Roberts, 1985 and Mason et al., 1985) 
while beta-dimers of inhibin stimulate FSH release (Ling et al., 
1986 and Vale et al., 1986). The homologous amino-acids in pro-
LH-RH 18-26 and the inhibin monomer precursor sequences shown in 
table 5.2 are more than likely to be the residues required for 
these biological effects on pituitary gonadotropes. , 
Another feature of the result obtained here is the fact that 
there is no difference in the size of the, DNA fragments that 
hybridize to probe LlO in normal subjects or patients suffering 
from Kallmann's Syndrome or Hypogonadal Hypogonadism (Kallman et 
a l ., 1944; Santoro et al., 1984). The LH-RH gene defect in 
these disorders is thus not due to any major deletions or 
insertions within the gene. Similar investigations carried out 
with Dr Mali Kelly (Columbia University Medical School) on 
several patients with these disorders and using the same probe 
have confirmed this conclusion. The defect in the human LH-RH 
gene is thus unlike that of the hypogonadal mouse where a major 
deletion of 33.5 Kb results in the exclusion of the last two 
exons of the gene (Mason et al., 1986). Further characterisation 
of the transcription units in the LH-RH gene should make it 
possible to investigate whether aberrations at these loci are 




5.4 LH-RH Gene Regulation Studies 
5.4.1 Introduction 
Ovariectorny results in high serum levels of LH in the female 
rat (for review see Fink, 1979). Estrogen replacement therapy 
reverses this effect of gonadectorny. This experimental model has 
established the feedback role of the steroid target hormone at 
the level of the pituitary and the hypothalamus (Arakis et al., 
1975; Fink, 1979). The frequency of LH-RH pulses in the 
hypophyseal portal blood in rats (Fink, 1979) and primates 
(Carmel et al., 1976; Neill, 1980) is similar to the frequency of 
LH pulsatility in the intact rat. However, continuous 
administration and or high doses of LH-RH ablates the LH response 
in a "paradoxical" manner (Belchetz, 1983; Bex and Corbin, 1984). 
It does not follow therefore that extremely elevated serum levels ~L~ 
are necessarily due to high portal blood levels of LH-RH. 
Furthermore, the initial negative feedback of estradiol at the 
level of the pituitary (decreased LH pulse arnplit~;!i)J i: l'K 
accompanied by no change in LH-RH pulse frequencyq.d This initial 
;' 'r,tt,-a 
effect of estradiol is followed by an increase in LH-RH pulse 
frequency (positive feedback) with concomitant changes in LH 
pulses and increased LH pulse amplitude (i.e. positive feedback 
at the pituitary level). Progesterone acts synergistically with 
estradiol to decrease LH-RH pulse frequency and to reinforce the 
negative and positive effects of estradiol at the pituitary 
level. These results were obtained in the ewe (Clarke, 1984), in 
the female rat in vivo (Sarkar and Fink, 1979; Sherwood and Fink, 
1980) and in female rat hypothalami in vitro (Kirn and Ramirez, 
1985). 
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Immunohistochemistry and more recently in situ hybridisation 
have demonstrated that the LH-RH neurons have their cell bodies 
in the diagonal band of Broca and in the preoptic area of the 
hypothalamus (King and Anthony, 1983; Silverman, A.J. et al., 
1978, 1979; Shivers et al., 1986). The LH-RH immunoreactive 
neurones do not appear to be directly affected by estradiol since 
they do not concentrate this steroid in their nuclei (Shivers et 
al., 1983). 
Since as few as 1000 forebrain neurons have been shown to 
synthesize LH-RH (Shivers et al., 1983) and since large amounts 
of Poly A RNA are required to visualize the LH-RH message on a 
Northern Blot, it was decided that the highly sensitive mRNA 
detection systems of in situ hybridisation and Sl nuclease 
mapping would have to be employed to study LH-RH gene expression 
in the ovariectomized-steroid replaced rat model system. Also, 
an experimental protocol most likely to establish a measurable 
difference in LH-RH mRNA was decided on. Thus, estradiol 
replacement was effected 14 or 21 days after ovariectomy (when 
serum LH values are extremely high). Estradiol was replaced by AJlof{ 
subcutaneous implants of silastic capsules containing estradiol Nf/_~ 
at 260 ug/ml in sesame oil. 1 cm of silastic capsule (outer ~w11 ~4 
l 
diameter 0.125 in; inner diameter 0.062 in) was implanted per 1oq 
, LC ;t.e(6 g of rat weight. This resulted in serum estradiol levels of 
+ 100 pg/ml by constant release over the 1 to 4 day period. The 
hypothalamic LH-RH mRNA content was measured one or four days 
after the commencement of replacement (when serum levels of LH 
have reached those of the intact animal). 
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5.4.2 Methods 
5.4.2.1 In Situ Hybridisation 
(a) Sectioning 
Prior to the collection of hypothalami, rats were 
anaesthetized with pentobarbitol and sytemically perifused with 
cold 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). 
Hypothalami were dissected from decapitated rats, embedded 
in Lipshaw M-1 embedding matrix and frozen in liquid nitrogen. 
Ten micrometer sections were cut on a cryostat and mounted on 
polylysine coated slides. Sections either in the vertical 
(sagittal) or horizontal planes were catalogued according to 
Paxinos' stereotaxic atlas of the rat brain and stored dessicated 
at -7o 0 c. 
(b) Prehybridisation 
Thawed sections were incubated for 10 min in 5 ug/ml 
proteinase K, washed in 2 x SSC (RNase-free) and overlayed with 
prehybridisation buffer (2.5 M NaCl, 0.5 M Tris (pH 7.5), 3% 
Ficoll, 3% PVP, 3% BSA, 125 mM EDTA, 5 mg/ml sonicated salmon 
sperm DNA, 10 mg/ml yeast total RNA, 25 mg/ml yeast tRNA and 50% 
formamide). Prehybridization was at 50°c for 2h in a humidified 
box containing Whatmans 3M paper saturated with 4 x SSC in 50% 
Formamide. 
(c) Probe Synthesis 
A complementary RNA probe was transcribed off the rat LH-RH 
cDNA in the pGem Vector using SP6 RNA polymerase. 2 ug of 
template DNA in a solution of 40 mM Tris/HCl (pH 7.5), 6 mM 
MgCl2, 2 mM spermidue, 500 uM rCTP, rGTP, and rATP, 0.7 mg/ml 
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DTT, 30 units RNasin and containing 500 pmoles of [alpha-3 5sJ-
UTP was used to make the cRNA probe by incubation for 20 min at 
37°c with 15 units of SP6 RNA polymerase. The UTP concentration 
was increased to 500 uM and the reaction continued for a further 
40 min. The DNA template was digested with RNase-free DNase and 
the solution was extracted with phenol:chloroform and 
precipitated from 2M NH4Ac with 2.5 vol of ethanol. The labelled 
RNA pellet was washed with 70% ethanol dried and stored at -20°c 
in TE. 
d) Hybridization and washing 
The probe was heated to 6o 0 c for 10 min and added to the 
tissue in hybridization buffer at a concentration of 2 50 
cpm/ul. Hybridization buffer was identical to prehybridization 
buffer except for the presence of 10% Dextran sulphate. 
Hybridization was allowed to proceed by overnight incubation 
in the humidified box at 50°c. The slides were washed at room 
temperature for 30 min with 2 x SSC. RNase A at 30 ug/ml in 0.5 
M NaCl, 10 mM Tris/HCl (pH 8.0) was added to the tissue to digest 
unhybridized probe by incubating at 37°c for 45 min. The slides 
were washed for 1 h in 4 1 of 2 x SSC at 50°c and for 3 h in 4 1 
of 0.1 x SSC, 0.05% NaPPi and 14 mM beta-mercaptoethanol. The 
solution was cooled to room temperature and washing continued 
overnight. The sections were then dehydrated through 50%, 70% 
and 90% ethanol containing 0.3 M NH4Ac for 2 min each. 
e) Visualization 
Slides were dried in a dessicator overnight and then dipped 
in Lipshaw NTB2 photographic emulsion at 42°c in the dark. 
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Slides were allowed to dry in the dark for 2 hand stored at 4°C 
for 14 days in a light box. The slides were developed and the 
distribution of silver grains analysed on a Leitz "TAS Plus" 
image analysis system by an independent investigator who did not 
know the experimental details nor the arrangement of the coded 
slides. 
// ,;~0~ 
5.4.2.2 Sl Nuclease mapping using oligonucleotide Lll vfl-~d~:; 
Poly A RNA was prepared from various tissues and individual 
rat hypothalami as outlined in 5.2.1.1 and 5.2.1.2. 
Oligonucleotide Lll was labelled as outlined in 5.2.l.3(e). 1 ug 
of test Poly A RNA, 10 ng of yeast tRNA and 5 x 10 5 cpm of the 
oligonucleotide were precipitated from 0.5 M NH4Ac with ethanol 
in an eppendorf tube, washed with 70% ethanol and evacuated dry. 
The pellet was dissolved in 30 ul of hybridization soltuion 
containing 400 rnM NaCl, 400 uM Na 2PIPES (pH 6.5), 1 rnM EDTA and 
80% deionized formamide. The solution was then incubated at 72°c 
for 15 min followed by 45°c for 18 h. 
Unprotected RNA and unhybridized oligonucleotide were 
digested with 100 units of Sl nuclease added in 100 ul of Sl 
buffer containing 0.25 M NaCl, 30 rnM Na OAc (pH 4.6, 1 rnM znso4 
and 20 ug/ml sonicated salmon sperm DNA. Digestion was allowed 
to proceed at 30°c for 40 min. The solution was extracted with 
phenol: chloroform. 10 ug of carrier tRNA was added, followed by 
300 ul of Ethanol. The tubes were incubated on crushed co2 for 
10 min and microcentrifuged for 1 hat 4°c. The pellet was 
washed with 70% ethanol, evacuated dry and redissolved in 10 ul 
of sequencing gel dye. 5 ul of sample was electrophoresed on a 
16% polyacrylamide, 50% urea, 1 x TBE denaturing gel in 1 x TBE 
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until the xylene cyanol migrated to a position 2/3rds down the 
length of the gel. The gel was sandwiched between two sheets of 
gel bond backing and directly autoradiographed at -70°c in the 
presence of Cronex amplifying screens. 
5.4.3 Distribution of silver grains 
The distribution of silver grains representing the presence 
of LH-RH mRNA containing cells on the tissue sections examined, 
followed the pattern expected for LH-RH neurones. Thus cell 
bodies in the diagonal band of Broca and in the pre-optic area ~u~J~. 
A few labelled cells were located in the _basal hypothalamus, 
ventral and lateral to the ventromedial nuclejs. No labelled 
cells were observed in the arcuate nucleus. The low background 
distribution of silver grains indicated that the unhybridized 
probe had been successfully digested by RNase. Tissue sections 
through the hypothalamus of three ovariectomized rats (14 days) 
and three ovariectomized 4-day estradiol-replaced rats were 
examined by an independent investigator from Amersham USA. The 
silver grain count representing LH-RH mRNA content and the 
position of the tissue section examined is presented in Table 
5.2. Fig. 5.7 shows the concentration of silver grains over a 
pre-optic area LH-RH neurone. 
The number of cells labelled in comparable sections in the 
two experimental groups was not different, but the average number 
of grains per cell was significantly higher in the steroid 
replaced group. This was true in case of the LH-RH cell bodies 
in the diagonal band of Broca, but the increase was greater in 
the case of the pre-optic area LH-RH neurons. The average grain 
count per cell increased by 83% overall in the steroid replaced 
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Fig. 5.7 IN SITU HYBRIDIZATION USING A RAT LH-RH PRECURSOR cDNA 
PROBE ON RAT PRE-OPTIC AREA SECTIONS 
10 micron frozen sections of rat hypothalamus were used 
to detect LH-RH mRNA containing neurones by in situ 
hybridization with a 35S-labelled cRNA probe. The 
diagonal band of Broca and the pre-optic area contained 
distinct cell bodies with fluorescent granules when 
examined under epiluminescence indicating the presence 

















No. of Ave. no. Total 
labeled cells silver grains silver grains 
oer cell 
8 123 . 991 
31 1 71 5303 
27 1 01 2752 
66 137 9046 
5 150 750 
28 285 7980 
19 237 4503 
52 254 13233 
Table 5.2 GnRH mRNA MEASURED IN RAT HYPOTHALAMIC SECTIONS BY IN 
SITU HYBRIDIZATION 
. ~ 
Cells were labelled with 3 ~S cRNA. After 14 days 
exposure, slides were developed and silver grains 
analysed on a Leitz "TAS Plus" image analysis system. 
The sections analysed transversed the diagonal band of 
Broca and the pre-optic area, where GnRH containing 
cells are located. The average silver grain count per 
cell increased by 83% overall when OVX rats were 






Anterior hypothalamic sections (plates 12-13 , 
Paxinos Stereotaxic Atlas of Rat Brain). 
Pre-optic area sections (plates 14-15, QP.~ cit). 
Horizontal sections (plates 54-56, op cit). 
Animals ovariectomized for 18 days. 
Animals ovariectomized for 14 days and estrogen 
replaced for 4 days. \ 
I ')(tl-{ 6-V ML i, f /J' ,1,0 I 
I ~ ''lf)t. { 4 (f , 
l ti l"'<f; • ac-r 
i ~ ~/.1,t f.l( r ·,/> q- J/ 
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ovariectomized rats. This could be interpreted as almost a 
doubling in the LH-RH RNA content of the cells after steroid 
replacement. 
In order to validate these results, the second method of RNA 
analysis was employed, viz. a sensitive Sl nuclease mRNA assay. 
Fig 5.8 shows that LH-RH mRNA was detectable by this assay in 
tissues known to contain the decapeptide. Longer exposure of 
this particular gel showed that shorter fragments were protected 
in the sheep hypothalamic poly A tract indicating that the sheep 
mRNA probably differs from the rat, human and mouse sequence in 
this region of the message. The high amounts of LH-RH mRNA in 
the ZR-75-1 cells as detected by this method of analysis confirms 
the result of the primer extension study (Fig. 5.3). 
Fig. 5.9 shows that within each experimental group of rats, 
similar levels of LH-RH mRNA were present. The rats replaced 
with estradiol for 1 day showed a significantly increased level 
of the LH-RH message above the level seen within the control 
group which received sesame oil implants. The increase in the 
LH-RH mRNA was even greater in the group of rats which received 
estradiol for 4 days. Thus the Sl assay results complemented the 
in situ hybridization results. 
It appears from these results that LH-RH mRNA levels 
increased while serum LH levels decreased in this model system. 
One possible explanation for this is that the high serum LH 
levels in the ovariectomized animal feed back at the hypothalamic )/~ 
level and inhibit LH-RH synthesis in an attempt to overcome the 
excessive LH release due to the removal of the negative feedback 
of estrogen at the pituitary. This short loop feedback is 
insufficient to overcome the removal of the negative effect of 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Fig. 5.8 St NUCLEASE SOLUTION PHASE HYBRIDIZATION ASSAY FOR THE 
LH-RH PRECURSOR mRNA USING PROBE L11 
LH-RH precursor encoding RNA was detected in the rat 
and human hypothalamus and the two breast tumour cell 















The 34-mer probe, Ll 1 , 
gel. 
Zero RNA control. 
E. coli RNA. 
Human hypothalamic RNA. 
Human pituitary RNA. 
Human placental RNA. 
Frog brain RNA. 
MDA-MB-231 RNA 
MDA-MB-231 RNA 
Rat pre-optic area RNA. 
Sheep hypothalamus RNA. 
Sheep pituitary RNA. 
Human liver RNA. 
ZR-75-1 RNA. 
loaded directly onto the 
(Prep 1 ) . 
(Prep 2) . 
1 11g of po 1 y-A RNA was used in the assay for a 11 the 
above tissues except for E. coli RNA where 10 11g total 
RNA was used. 
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OVx OVX + E2 10 OVX + E2 40 
34 -S1 +S1 1 2 3 1 2 3 4 1 2 3 4 I 
I I I 
. 
Fiq. 5.9 QUANTITATION OF RNA FROM OVARIECTOMIZED COVX) AND 
OVARIECTOMIZED-ESTRADIOL REPLACED COVX+E2> RATS. 
Adult female Sprague-Dawley rats were ovariectomized 
for 21 days. Three rats were given implants of 
silastic capsules containing sesame oil (controls) 
while eight rats received estradiol-containing silastic 
capsule implants. Four of the latter group were 
sacrificed after 1 day of replacement while the 
remaining 4 were sacrificed together with the 3 control 
rats after 4 days of replacement. 1 µg of poly-A RNA 
from the pre-optic area of individual rats was assayed 
for LH-RH mRNA by the Sl nuclease protection assay 
using probe Lll. LH-RH mRNA levels were elevated in 
the estradio 1 rep laced rats. Since LH levels in the 
serum had decreased in these animals, the LH-RH mRNA 
seems to be reciprocally regulated relative to the 
serum LH levels in this model system. 
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estrogen i.e. high serum levels of LH persist while LH-RH mRNA 
(? LH-RH synthesis) has decreased. Evidence supporting this 
explanation comes from a single experiment carried out by Dr M. 
Blum (in the laboratory of Dr J. Roberts, Columbia University) 
where estradiol replacement in ovariectomized, hypophysectomized 
rats did not result in an increase in LH-RH mRNA. Thus some 
pituitary factor is required for steroid replacement to cause an 
increase in hypothalamic LH-RH mRNA. 
The results obtained here were also obtained in the 
laboratory of Dr D.W. Pfaff (Pfaff, 1986). The difference in 
GnRH mRNA after steroid treatment of gonadectomized rats is in 
accordance with hypothalamic precursor levels and peptide content 
(Millar et al., 1977b, 1981) and LH-RH release (Goddard et al., 
1981) in this model system. These studies indicate that steroids 
(estradiol in females and tastosterone in males) have a positive 
feedback effect on LH-RH synthesis and secretion but an over-
• riding negative feedback on LH-production and release. 
Experiments will have to be executed in other model systems 
to establish the relationship of LH-RH mRNA (and hypothalamic LH-
RH precursor levels, LH-RH peptide content and LH-RH release) to 
pituitary LH synthesis and release. This will establish whether 
the inverse relation of LH-RH mRNA levels to circulating LH is a 
general phenomenon. Kinetic experiments should be particularly 
useful in this respect. 
It has recently been demonstrated that pro TRH mRNA levels 
undergo an almost two fold increase in hypothyroid animals (low 
pituitary TSH and low circulating Thyroid hormone levels). This 
·ncrease is obliterated by levothyroxine treatment, suggesting an 
inverse relation between circulating Thyroid Hormone (and 
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• 
therefore pituitary TSH) and pro TRH mRNA (Segerson et al., 
1987). Whether there is a general inverse relation between 
circulating levels of pituitary hormones and the mRNA of their 
releasing factors needs to be further investigated. 
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CHAPTER 6 
SUMMARY AND CONCLUSIONS 
6.1 INTRODUCTION 
The idea that polypeptide hormones exist in more than one 
molecular form was first formulated in 1902 when prosecretin was 
postulated as a precursor of secretin (Bayliss et al., 1902). It 
was only in 1964 that chemical evidence was provided for 
molecular variation in polypeptide hormones, when two gastrin 
heptadecapeptides differing in the presence or absence of a 
sulphate group on the tyrosine were described (Gregory et al., 
1964). This theme has now been established for a wide variety of 
peptide hormones. When this thesis was commenced, there was no __ 
evidence for a LH-RH family of peptides. A number of vertebrate ,,---, 
hypothalamic LH-RHs have since This thesis 
describes immunological chromatographic and nucleic acid 
hybridization studies confirming that a number of LH-RH-like 
peptides and genes/mRNAs exist in a variety of mammalian tissues. 
In order to investigate the biosynthesis of LH-RH, in vitro 
translation, oligonucleotide hybridization, primer extension, Sl 
nuclease assay and cDNA library construction and analysis 
techniques were employed. To address the issue of LH-RH gene 
copy number and gene structural diversity, genomic restriction 
endonuclease fragments were screened for LH-RH precursor encoding 
sequences. 
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6.2 LH-RH: PEPTIDE DISTRIBUTION AND MOLECULAR HETEROGENEITY 
This study confirms a wide tissue distribution for LH-RH and 
structurally related peptides. The extrahypothalamic brain, the 
gut and the gonads are regions now known to share a wide variety 
of identical or structurally similar peptides (Yalow et al., 
1981). The extensive distribution of LH-RH-IR in these and other 
rat tissues would seem to support Niall's "second rule of peptide 
evolution", viz. that "everything is made everywhere" (Niall, 
1982). 
Indications that the LH-RH-IR in some of the tissues 
investigated is structurally distinct from the hypothalamic 
decapeptide, come from the fact that non-parallel displacement 
curves are obtained in the radioimmunoassay of extracts of these 
tissues. 
The different estimation of the LH-RH-IR in gonadal and HEp-
3 tumour extracts by antibodies directed at different parts of 
the LH-RH peptide, underscores the structural dissimilarity 
between the peptides in these tissues and the hypothalamic 
peptide. The multiple molecular forms of LH-RH-IR seen in HPLC 
elution prophiles of the testicular or HEp-3 extracts indicate 
that they contain LR-RH-like peptides which are distinct from the 
known vertebrate forms. HEp-3 extracts do, however, contain a 
peptide that co-elutes with the mammalian hypothalamic peptide, 
while gonadal extracts have a peptide that elutes in a position 
similar to chicken II LH-RH. 
6.3 LH-RH BIOSYNTHESIS mRNA STUDIES 
LH-RH immunoreactivity is associated with membrane bound 
ribosomes as is the case with other secreted polypeptides. The 
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injection of hypothalamic poly A mRNA into Xenopus oocytes 
results in the translation ad export of immuno-assayable LH-RH 
I~/ 
into the incubation medium. d Northern blot analysis of RNA from 
sheep hypothalami, rat hypothalami, total rat brain, and the 
HEp-3 tumour with oligonucleotide probes for LH-RH coding 
sequences, indicate the presence of a number of mRNAs which 
hybridize to the probes. Primer extension assays, the DNA 
sequence of a rat hypothalamic cDNA clone and the human placental 
LH-RH cDNA sequence are consistent with 2 transcription sites 
within the LH-RH gene. The LH-RH mRNA in the ovariectomized-
steroid replaced rat model appears to be reciprocally regulated 
relative to the serum LH levels. 
6.4 LH-RH: GENE ANALYSIS 
Southern blots of restriction endonuclease digested human 
DNA probed with a number of oligonucleotides showed hybridizing 
fragments identical in size to those initially detected by the 
group of Peter Seeburg. An 18-mer probe derived from the amino 
acid sequence immediately C-terminal to the LH-RH decapeptide in 
the human LH-RH precursor hybridized to at least two other DNA 
fragments for each restriction enzyme. These results are 
consistent with the existence of other genes carrying coding 
sequences for a peptide similar to LH-RH. The inhibin, betaTGF 
family of genes was seen to share sequence homology with the 
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1. Cauliflower Mosaic Virus Coot Protein 
2. Pig Lactate Dehydrogenase 
3. Bokers Yeost ATPase Protein 3/6 
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23. Mouse/Bakers Yeast Cytochrome b 
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AMINO ACID SEQUENCE: 
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CJ Mommolion LH-RH 
D Chicken I LH-RH 
@ Salmon LH-RH 
O Lamprey LH-RH 
' Chicken n LH-RH 
Table 6,.2 POLYPEPTIDES WITH SEQUENCES HOMOLOGOUS TO VERTEBRATE 
LH-RHs 
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6.5 LH-RH-LIKE SEQUENCES IN KNOWN POLYPEPTIDES 
Five vertebrate hypothalamic LH-RHs have been isolated to 
date. Table 6.1 shows that the LH-RH of the primitive agnathan 
vertebrate, the lamprey, is most divergent from the mammalian 
peptide, having 5 different amino acids. The avian peptide 
GlnB-LH-RH is the least different and a peptide with similar 
chromatographic properties has recently been described in the 
ovine pineal gland (Millar et al., 1986). 
A search of the Margaret Dayhoff protein sequence data bank 
revealed a large number of proteins ranging from a hypothetical 
plasmid protein to a number of human proteins which have at least 
four amino acids co-incident with those of LH-RH (Table 6.1). 
The high scores achieved by 
mutation data matrix search 
ancestral origin with LH-RH. 
some of these proteins in the J f 1f 0u~ 
programme is suggestive of a common 
Table 6.2 demonstrates that when 
compared with the other vertebrate LH-RHs there is even more 
homology between some of these proteins and the hypothalamic 
decapeptide. 
In view of the large number of mammalian proteins having 
structural homology with LH-RH, and since it is known that at 
le~ ~ three amino acids are required for an immunogenic site, it 
is quite possible that some of the proteins listed in Tables 6.1 
and 6.2 may cross-react significantly with certain LH-RH antisera 
when mammalian extrahypothalamic tissue extracts are assayed. 
These findings have important implications regarding the 
possible biological activity of some of these proteins and 
peptides in systems analogous or comparable to the release of 
pituitary gonadotropins by LH-RH. Yeast alpha mating factor has 
been shown to not only bind specifically to rat pituitary cells 
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but also to stimulate LH-release (Loumaye et al., 1982). Chicken 
gastrin-releasing peptide stimulates the release of LH from 
chicken pituitary cells to a greater degree than does yeast alpha 
mating factor (King, J.A. unpublished). Also, prolactin has been 
shown to compete, albeit at relatively high concentrations, in a / 
rat pituitary LH-RH receptor binding assay (Millar, R.P. 
unpublished). The fact that LH-RH-like peptide sequences are 
found in the simplest life forms has relevance to the current 
theories regarding the evolution of the neuroendocrine system. 
In 1969, Pearse proposed that the endocrine system had developed 
as an ''outpouch" of the brain (Pearse, 1969). Thus, the cells of 
the diffuse neuroendocrine system" had their origin in the 
neuroectoderm (the nervous system therefore being a precursor of 
the endocrine system). An alternate theory, which is more 
consistent with the fact that the common biochemical elements of 
the nervous and endocrine system occur in some unicellular 
organisms, is that the two systems have a common early 
evolutionary origin (Leroith et al., 1982). The occurence of the 
LH-RH-like peptide sequences in the simplest organisms is more 
consistent with the latter theory. 
6.6 OTHER BIOLOGICAL ACTIVITIES OF LH-RH 
The wide distribution of LH-RH and LH-RH receptors outside 
the hypothalamo-hypophyseal system is highly suggestive that the 
peptide and/or its structural analogues have other biological 
functions. 
6.6.1 Central Nervous System Roles 
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The extrahypothalamic LH-RH neuronal pathways suggest 
neurotransmitter/neuromodulator roles for the peptide. Further 
support for such roles come from the following observations. 
Excitatory effects have been observed for iontophoretically 
applied LH-RH in the arcuate nucleus and other brain regions 
(Moss et al., 1978). Also, stimulation of frog sympathetic 
preganglionic fibres results in a slow excitatory post-synaptic 
potential that can be mimicked by exogenous LH-RH and blocked by 
LH-RH antagonists (Jan et al., 1979). 
6.6.2 Reproductive System Roles 
At the level of the gonad, LH-RH receptors have been 
demonstrated on ovarian granulosa and luteal cells, and 
C ("'U I f.t? 
f ,t lul((,(,"!,,N 
testicular Leydig cells. The presence of a LH-RH-like peptide in 
pvarian granulosa cells and testicular Sertoli cells suggests a 
paracrine role for the peptide in the regulation of gonadal 
function. The direct effects of exogenous LH-RH on gonadal LH-
and FSH receptors, steroidogenic enzymes and steriodogenesis 
implicate ~cally produced peptide at all these levels of 
gonadal f n ~ (Hsueh et al., 1981). LH-RH has dramatic 
effects on the growth of accessory sex organs in both males and 
females. In the male this is due to an antiandrogenic effect of 
the peptide (Pedroza et al., 1980). Thus, androgen-dependent 
prostate tumour growth is also inhibited by LH-RH (Labrie et al., 
1986). In females inhibition of uterine growth may be due to 
direct effects on the uterus (Sundaram et al., 1981). The 
possibility thus exists for a growth inhibitory role of the 
endogenous peptide at the level of the accessory organs. 
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In patients with bone metastases of prostate tumours, 
treatment with LH-RH brings about relief of bone pain. Whether 
the endogenous gonadal peptide can influence steroid production 
to influence pain pathways under normal circumstances is also a 
-matter of speculation. 
6.6.3 Roles in Other Physiological Systems 
In the placenta the LH-RH located in the cytotrophoblasts 
may stimulate the release of hCG from the syncytiotrophoblasts 
(Hsueh et al., 1981). 
At the level of the adrenal where LH-RH receptors occur, LH-
RH has been shown to inhibit angiotensin II binding to the 
adrenal and some LH-RH agonists increase aldosterone production 
(Capponi et al., 1979). Receptors in the adrenals suggest the 
presence of a local peptide which may regulate steroidogenesis at 
~,o<..-4-. 
this nonreproductive organ (Bernado et al., 1978).~ Such a 
peptide has been described in the frog adrenal medulla (Eiden et 
al., 1980). The LH-RH in milk has been implicated as an exocrine 
hormone, which is transported through the mother's milk to affect 
sexual development of neonates (Hazum, 1983). Since LH-RH 
receptors are found in mammary carcinomas and since growth of 
these tumours is inhibited by LH-RH analogs, the peptide may 
function as either a paracrine regulator of normal mammary 
function or an autocrine growth regulator (Eidne et al., 1975). 
In this regard it is interesting to note that bombesin which 
shares homology with the C-terminal chicken gastrin-releasing 
peptide is an autocrine growth regulator of small cell lung 
carcinomas (Cuttitta et al., 1985). LH-RH, on the other hand, 
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shares homology with the N-terminus of chicken gastrin-releasing 
peptide (Table 6.1). 
LH-RH also has biological activities in the islets of the 
pancreas. Here the peptide is known to inhibit insulin release 
(Klier et al., 1980). The endogenous peptide may thus be 
involved in the control of glucose metabolism. 
The fact that LH-RH is present in the retina and the 
olfactory bulbs, and since patients with the LH-RH deficiency 
disease , Kallmann's syndrome j sometimes present with colour 
blindness and anosmia may implicate the peptide in these two 
sensory systems. ( g vtA l'-'vl- ?~ ts itc ( 
The above observations provide significant support for a 
variety of biological functions for endogenous, widely 
distributed LH-RH-like peptides distinct from the gonadotropin 
releasing activity of LH-RH in the hypothalamic-pituitary system. 
The structurally distinct peptides described in this thesis may 
therefore be endogenous regulators of some of these biological 
systems. The functional relevance of the LH-RH family of peptide 
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